CN1070500C - Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis - Google Patents
Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis Download PDFInfo
- Publication number
- CN1070500C CN1070500C CN94192745A CN94192745A CN1070500C CN 1070500 C CN1070500 C CN 1070500C CN 94192745 A CN94192745 A CN 94192745A CN 94192745 A CN94192745 A CN 94192745A CN 1070500 C CN1070500 C CN 1070500C
- Authority
- CN
- China
- Prior art keywords
- xaa
- leu
- glu
- lys
- arg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108700020797 Parathyroid Hormone-Related Proteins 0.000 title claims abstract description 69
- 102000043299 Parathyroid hormone-related Human genes 0.000 title claims abstract description 69
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 20
- 108090000445 Parathyroid hormone Proteins 0.000 title claims abstract description 15
- 238000011282 treatment Methods 0.000 title claims abstract description 8
- 230000015572 biosynthetic process Effects 0.000 title claims description 7
- 102000003982 Parathyroid hormone Human genes 0.000 title description 4
- 239000000199 parathyroid hormone Substances 0.000 title description 4
- 229960001319 parathyroid hormone Drugs 0.000 title description 2
- 238000003786 synthesis reaction Methods 0.000 title description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 113
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 83
- 229920001184 polypeptide Polymers 0.000 claims abstract description 82
- 150000001413 amino acids Chemical class 0.000 claims abstract description 75
- 238000000034 method Methods 0.000 claims abstract description 46
- 102100036893 Parathyroid hormone Human genes 0.000 claims abstract description 37
- 150000003839 salts Chemical class 0.000 claims abstract description 34
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 15
- 230000008569 process Effects 0.000 claims abstract description 14
- 241000124008 Mammalia Species 0.000 claims abstract description 9
- 238000010532 solid phase synthesis reaction Methods 0.000 claims abstract description 9
- 101150071808 PTHLH gene Proteins 0.000 claims abstract 11
- 150000001875 compounds Chemical class 0.000 claims description 45
- 108090000623 proteins and genes Proteins 0.000 claims description 39
- 229920005989 resin Polymers 0.000 claims description 34
- 239000011347 resin Substances 0.000 claims description 34
- REWSWYIDQIELBE-FXQIFTODSA-N Ala-Val-Ser Chemical group [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O REWSWYIDQIELBE-FXQIFTODSA-N 0.000 claims description 27
- KYIIALJHAOIAHF-KKUMJFAQSA-N Leu-Leu-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 KYIIALJHAOIAHF-KKUMJFAQSA-N 0.000 claims description 25
- XOIATPHFYVWFEU-DCAQKATOSA-N Glu-His-Gln Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)N XOIATPHFYVWFEU-DCAQKATOSA-N 0.000 claims description 21
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 claims description 19
- LBOVBQONZJRWPV-YUMQZZPRSA-N Asp-Lys-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O LBOVBQONZJRWPV-YUMQZZPRSA-N 0.000 claims description 18
- BRQKGRLDDDQWQJ-MBLNEYKQSA-N His-Thr-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O BRQKGRLDDDQWQJ-MBLNEYKQSA-N 0.000 claims description 18
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 claims description 18
- 108010015792 glycyllysine Proteins 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 18
- UXJCMQFPDWCHKX-DCAQKATOSA-N Arg-Arg-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O UXJCMQFPDWCHKX-DCAQKATOSA-N 0.000 claims description 17
- 108010048734 sclerotin Proteins 0.000 claims description 15
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 claims description 13
- 229920001427 mPEG Polymers 0.000 claims description 9
- ILWHFUZZCFYSKT-AVGNSLFASA-N Glu-Lys-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O ILWHFUZZCFYSKT-AVGNSLFASA-N 0.000 claims description 7
- 101001135767 Rattus norvegicus Parathyroid hormone Proteins 0.000 claims description 7
- 238000005336 cracking Methods 0.000 claims description 7
- XEYMBRRKIFYQMF-GUBZILKMSA-N Gln-Asp-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O XEYMBRRKIFYQMF-GUBZILKMSA-N 0.000 claims description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
- 150000002596 lactones Chemical class 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 claims description 4
- 235000017803 cinnamon Nutrition 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 201000010934 exostosis Diseases 0.000 claims description 4
- 201000010930 hyperostosis Diseases 0.000 claims description 4
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 claims description 3
- CEXFELBFVHLYDZ-XGEHTFHBSA-N Thr-Arg-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O CEXFELBFVHLYDZ-XGEHTFHBSA-N 0.000 claims description 3
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 claims description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 claims description 2
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 claims description 2
- PVSNBTCXCQIXSE-JYJNAYRXSA-N Arg-Arg-Phe Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PVSNBTCXCQIXSE-JYJNAYRXSA-N 0.000 claims description 2
- 229940126545 compound 53 Drugs 0.000 claims description 2
- 108010073025 phenylalanylphenylalanine Proteins 0.000 claims description 2
- JOSAKOKSPXROGQ-BJDJZHNGSA-N Lys-Ser-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JOSAKOKSPXROGQ-BJDJZHNGSA-N 0.000 claims 5
- PMQXMXAASGFUDX-SRVKXCTJSA-N Ala-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CCCCN PMQXMXAASGFUDX-SRVKXCTJSA-N 0.000 claims 1
- 241000723347 Cinnamomum Species 0.000 claims 1
- AUTNXSQEVVHSJK-YVNDNENWSA-N Glu-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O AUTNXSQEVVHSJK-YVNDNENWSA-N 0.000 claims 1
- YAALVYQFVJNXIV-KKUMJFAQSA-N His-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CN=CN1 YAALVYQFVJNXIV-KKUMJFAQSA-N 0.000 claims 1
- WVJNGSFKBKOKRV-AJNGGQMLSA-N Lys-Leu-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WVJNGSFKBKOKRV-AJNGGQMLSA-N 0.000 claims 1
- KDYPMIZMXDECSU-JYJNAYRXSA-N Phe-Leu-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 KDYPMIZMXDECSU-JYJNAYRXSA-N 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 claims 1
- 239000007790 solid phase Substances 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000010188 recombinant method Methods 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 121
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 104
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 98
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 84
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 78
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 78
- 238000010265 fast atom bombardment Methods 0.000 description 72
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 69
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 69
- 229940024606 amino acid Drugs 0.000 description 68
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 66
- 235000001014 amino acid Nutrition 0.000 description 65
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 60
- 210000000988 bone and bone Anatomy 0.000 description 38
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 32
- -1 His Chemical compound 0.000 description 30
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 22
- 239000013612 plasmid Substances 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 20
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 15
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 13
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 13
- 239000002253 acid Substances 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 10
- QJPWUUJVYOJNMH-VKHMYHEASA-N L-homoserine lactone Chemical compound N[C@H]1CCOC1=O QJPWUUJVYOJNMH-VKHMYHEASA-N 0.000 description 10
- CQQGCWPXDHTTNF-GUBZILKMSA-N Leu-Ala-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O CQQGCWPXDHTTNF-GUBZILKMSA-N 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 239000011575 calcium Substances 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 230000002209 hydrophobic effect Effects 0.000 description 10
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 9
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 210000002997 osteoclast Anatomy 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- ZOWOHMFPXMYFKJ-WBTWNKCNSA-N (4S)-4-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]acetyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]propanoyl]amino]-5-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(1S)-1-carboxyethyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](C)N)C(C)C)[C@@H](C)CC)C1=CN=CN1 ZOWOHMFPXMYFKJ-WBTWNKCNSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 208000006386 Bone Resorption Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- MWMJCGBSIORNCD-AVGNSLFASA-N Glu-Leu-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O MWMJCGBSIORNCD-AVGNSLFASA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229910021529 ammonia Inorganic materials 0.000 description 6
- 230000024279 bone resorption Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000013270 controlled release Methods 0.000 description 6
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 229930182817 methionine Natural products 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- WVYJNPCWJYBHJG-YVNDNENWSA-N Glu-Ile-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O WVYJNPCWJYBHJG-YVNDNENWSA-N 0.000 description 5
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 238000007334 copolymerization reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- HMRWQTHUDVXMGH-GUBZILKMSA-N Ala-Glu-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN HMRWQTHUDVXMGH-GUBZILKMSA-N 0.000 description 4
- DXTYEWAQOXYRHZ-KKXDTOCCSA-N Ala-Phe-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N DXTYEWAQOXYRHZ-KKXDTOCCSA-N 0.000 description 4
- WIDVAWAQBRAKTI-YUMQZZPRSA-N Asn-Leu-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O WIDVAWAQBRAKTI-YUMQZZPRSA-N 0.000 description 4
- MYLZFUMPZCPJCJ-NHCYSSNCSA-N Asp-Lys-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O MYLZFUMPZCPJCJ-NHCYSSNCSA-N 0.000 description 4
- 208000010392 Bone Fractures Diseases 0.000 description 4
- 206010017076 Fracture Diseases 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 4
- BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 4
- 208000029725 Metabolic bone disease Diseases 0.000 description 4
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 4
- 108700005078 Synthetic Genes Proteins 0.000 description 4
- 108010049264 Teriparatide Proteins 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000010072 bone remodeling Effects 0.000 description 4
- PCWZHTGDXLRULT-UHFFFAOYSA-N buta-1,3-dienylbenzene styrene Chemical compound C(=C)C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 PCWZHTGDXLRULT-UHFFFAOYSA-N 0.000 description 4
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 4
- 230000001582 osteoblastic effect Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 3
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 3
- ULBHWNVWSCJLCO-NHCYSSNCSA-N Arg-Val-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N ULBHWNVWSCJLCO-NHCYSSNCSA-N 0.000 description 3
- AXXCUABIFZPKPM-BQBZGAKWSA-N Asp-Arg-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O AXXCUABIFZPKPM-BQBZGAKWSA-N 0.000 description 3
- 239000004380 Cholic acid Substances 0.000 description 3
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 3
- XJQDHFMUUBRCGA-KKUMJFAQSA-N His-Asn-Phe Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O XJQDHFMUUBRCGA-KKUMJFAQSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- HVAUKHLDSDDROB-KKUMJFAQSA-N Lys-Lys-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O HVAUKHLDSDDROB-KKUMJFAQSA-N 0.000 description 3
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 3
- 206010049088 Osteopenia Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- AIISTODACBDQLW-WDSOQIARSA-N Trp-Leu-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 AIISTODACBDQLW-WDSOQIARSA-N 0.000 description 3
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 108010062796 arginyllysine Proteins 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 235000019416 cholic acid Nutrition 0.000 description 3
- 229960002471 cholic acid Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940126540 compound 41 Drugs 0.000 description 3
- 229940125936 compound 42 Drugs 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 3
- 238000010612 desalination reaction Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- PLVPPLCLBIEYEA-WAYWQWQTSA-N (z)-3-(1h-indol-3-yl)prop-2-enoic acid Chemical compound C1=CC=C2C(\C=C/C(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-WAYWQWQTSA-N 0.000 description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- 241000024188 Andala Species 0.000 description 2
- WMEVEPXNCMKNGH-IHRRRGAJSA-N Arg-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N WMEVEPXNCMKNGH-IHRRRGAJSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- KKCUFHUTMKQQCF-SRVKXCTJSA-N Glu-Arg-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O KKCUFHUTMKQQCF-SRVKXCTJSA-N 0.000 description 2
- UPOJUWHGMDJUQZ-IUCAKERBSA-N Gly-Arg-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UPOJUWHGMDJUQZ-IUCAKERBSA-N 0.000 description 2
- IUKIDFVOUHZRAK-QWRGUYRKSA-N Gly-Lys-His Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 IUKIDFVOUHZRAK-QWRGUYRKSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- JWTKVPMQCCRPQY-SRVKXCTJSA-N His-Asn-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JWTKVPMQCCRPQY-SRVKXCTJSA-N 0.000 description 2
- VOKCBYNCZVSILJ-KKUMJFAQSA-N His-Asn-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC2=CN=CN2)N)O VOKCBYNCZVSILJ-KKUMJFAQSA-N 0.000 description 2
- WRPDZHJNLYNFFT-GEVIPFJHSA-N His-Thr Chemical compound C[C@@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N)O WRPDZHJNLYNFFT-GEVIPFJHSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- CNPNWGHRMBQHBZ-ZKWXMUAHSA-N Ile-Gln Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O CNPNWGHRMBQHBZ-ZKWXMUAHSA-N 0.000 description 2
- GECLQMBTZCPAFY-PEFMBERDSA-N Ile-Gln-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N GECLQMBTZCPAFY-PEFMBERDSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- HQUXQAMSWFIRET-AVGNSLFASA-N Leu-Glu-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN HQUXQAMSWFIRET-AVGNSLFASA-N 0.000 description 2
- POMXSEDNUXYPGK-IHRRRGAJSA-N Leu-Met-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N POMXSEDNUXYPGK-IHRRRGAJSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- ATIPDCIQTUXABX-UWVGGRQHSA-N Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ATIPDCIQTUXABX-UWVGGRQHSA-N 0.000 description 2
- 101100177977 Magnaporthe oryzae (strain 70-15 / ATCC MYA-4617 / FGSC 8958) PTH3 gene Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- NIOYDASGXWLHEZ-CIUDSAMLSA-N Ser-Met-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O NIOYDASGXWLHEZ-CIUDSAMLSA-N 0.000 description 2
- JGUWRQWULDWNCM-FXQIFTODSA-N Ser-Val-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O JGUWRQWULDWNCM-FXQIFTODSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 2
- 238000005377 adsorption chromatography Methods 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 238000005915 ammonolysis reaction Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229940073608 benzyl chloride Drugs 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000008416 bone turnover Effects 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 108700003690 bovine parathyroid hormone (1-34) Proteins 0.000 description 2
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical class [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940127271 compound 49 Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- PLVPPLCLBIEYEA-UHFFFAOYSA-N indoleacrylic acid Natural products C1=CC=C2C(C=CC(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000004898 n-terminal fragment Anatomy 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- 235000017103 tryptophane Nutrition 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 1
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- JWUBBDSIWDLEOM-UHFFFAOYSA-N 25-Hydroxycholecalciferol Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CCC1=C JWUBBDSIWDLEOM-UHFFFAOYSA-N 0.000 description 1
- 239000003872 25-hydroxy-cholecalciferol Substances 0.000 description 1
- OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 1
- SBVJJNJLFWSJOV-UBHSHLNASA-N Arg-Ala-Phe Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SBVJJNJLFWSJOV-UBHSHLNASA-N 0.000 description 1
- XPSGESXVBSQZPL-SRVKXCTJSA-N Arg-Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XPSGESXVBSQZPL-SRVKXCTJSA-N 0.000 description 1
- UISQLSIBJKEJSS-GUBZILKMSA-N Arg-Arg-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(O)=O UISQLSIBJKEJSS-GUBZILKMSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- JNNVNVRBYUJYGS-CIUDSAMLSA-N Asp-Leu-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O JNNVNVRBYUJYGS-CIUDSAMLSA-N 0.000 description 1
- SCQIQCWLOMOEFP-DCAQKATOSA-N Asp-Leu-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O SCQIQCWLOMOEFP-DCAQKATOSA-N 0.000 description 1
- AYFVRYXNDHBECD-YUMQZZPRSA-N Asp-Leu-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O AYFVRYXNDHBECD-YUMQZZPRSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- 235000021318 Calcifediol Nutrition 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 101100031571 Danio rerio pth4 gene Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- OGMQXTXGLDNBSS-FXQIFTODSA-N Glu-Ala-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O OGMQXTXGLDNBSS-FXQIFTODSA-N 0.000 description 1
- DYFJZDDQPNIPAB-NHCYSSNCSA-N Glu-Arg-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O DYFJZDDQPNIPAB-NHCYSSNCSA-N 0.000 description 1
- VSLXGYMEHVAJBH-DLOVCJGASA-N His-Ala-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O VSLXGYMEHVAJBH-DLOVCJGASA-N 0.000 description 1
- VHHYJBSXXMPQGZ-AVGNSLFASA-N His-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CN=CN1)N VHHYJBSXXMPQGZ-AVGNSLFASA-N 0.000 description 1
- BXOLYFJYQQRQDJ-MXAVVETBSA-N His-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CN=CN1)N BXOLYFJYQQRQDJ-MXAVVETBSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- DTGKSKDOIYIVQL-MRTMQBJTSA-N Isoborneol Natural products C1C[C@@]2(C)[C@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-MRTMQBJTSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- YWYQSLOTVIRCFE-SRVKXCTJSA-N Leu-His-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(O)=O YWYQSLOTVIRCFE-SRVKXCTJSA-N 0.000 description 1
- LXKNSJLSGPNHSK-KKUMJFAQSA-N Leu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N LXKNSJLSGPNHSK-KKUMJFAQSA-N 0.000 description 1
- RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 1
- DCRWPTBMWMGADO-AVGNSLFASA-N Lys-Glu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DCRWPTBMWMGADO-AVGNSLFASA-N 0.000 description 1
- NKKFVJRLCCUJNA-QWRGUYRKSA-N Lys-Gly-Lys Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN NKKFVJRLCCUJNA-QWRGUYRKSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- NEIXQLKURTVWCD-UHFFFAOYSA-N P(O)(O)N.P(N)(O)(O)=O Chemical compound P(O)(O)N.P(N)(O)(O)=O NEIXQLKURTVWCD-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- METZZBCMDXHFMK-BZSNNMDCSA-N Phe-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N METZZBCMDXHFMK-BZSNNMDCSA-N 0.000 description 1
- QTVUPXHPSXZJKH-ULQDDVLXSA-N Phe-Met-His Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N QTVUPXHPSXZJKH-ULQDDVLXSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 206010039984 Senile osteoporosis Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- BRGQQXQKPUCUJQ-KBIXCLLPSA-N Ser-Glu-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BRGQQXQKPUCUJQ-KBIXCLLPSA-N 0.000 description 1
- ZIFYDQAFEMIZII-GUBZILKMSA-N Ser-Leu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZIFYDQAFEMIZII-GUBZILKMSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- NSOXQYCFHDMMGV-UHFFFAOYSA-N Tetrakis(2-hydroxypropyl)ethylenediamine Chemical group CC(O)CN(CC(C)O)CCN(CC(C)O)CC(C)O NSOXQYCFHDMMGV-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- JFDGVHXRCKEBAU-KKUMJFAQSA-N Tyr-Asp-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N)O JFDGVHXRCKEBAU-KKUMJFAQSA-N 0.000 description 1
- YFOCMOVJBQDBCE-NRPADANISA-N Val-Ala-Glu Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N YFOCMOVJBQDBCE-NRPADANISA-N 0.000 description 1
- VIKZGAUAKQZDOF-NRPADANISA-N Val-Ser-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O VIKZGAUAKQZDOF-NRPADANISA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 1
- 210000003892 absorptive cell Anatomy 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- BJFLSHMHTPAZHO-UHFFFAOYSA-N benzotriazole Chemical compound [CH]1C=CC=C2N=NN=C21 BJFLSHMHTPAZHO-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 108700027323 bovine parathyroid hormone Proteins 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000006251 butylcarbonyl group Chemical group 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- JWUBBDSIWDLEOM-DTOXIADCSA-N calcidiol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C JWUBBDSIWDLEOM-DTOXIADCSA-N 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000007265 chloromethylation reaction Methods 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000002187 fatty acyl carnitines Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 108010028295 histidylhistidine Proteins 0.000 description 1
- 210000004124 hock Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 201000000916 idiopathic juvenile osteoporosis Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108010000761 leucylarginine Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- ZBELDPMWYXDLNY-UHFFFAOYSA-N methyl 9-(4-bromo-2-fluoroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate Chemical compound C12=C3SC(C(=N)OC)=NC3=CC=C2N=CN=C1NC1=CC=C(Br)C=C1F ZBELDPMWYXDLNY-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- CUXQLKLUPGTTKL-UHFFFAOYSA-M microcosmic salt Chemical compound [NH4+].[Na+].OP([O-])([O-])=O CUXQLKLUPGTTKL-UHFFFAOYSA-M 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 description 1
- YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 1
- MHZSEPBBOTVGFW-UHFFFAOYSA-N pyrrolidin-1-ylphosphane Chemical compound PN1CCCC1 MHZSEPBBOTVGFW-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 101150075675 tatC gene Proteins 0.000 description 1
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 101150044170 trpE gene Proteins 0.000 description 1
- 150000003654 tryptophanes Chemical class 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Synthetic polypeptide analogs of parathyroid hormone PTH, parathyroid hormone related peptide PTHrp, and of the physiologically active truncated homologs and analogs of PTH and PTHrp, in which amino acid residues(22-31) form an amphipathic alpha-helix, said residues(22-31) selected from hydrophilic amino acids(Haa) and lipophilic amino acids(Laa) ordered in the sequence: Haa(Laa Laa Haa Haa)2 Laa and their pharmaceutically acceptable salts are useful for the prophylaxis and treatment of osteoporosis in mammals. Processes for the production of the polypeptides via solid phase and recombinant methods are provided.
Description
Background of invention
A) invention field
The present invention relates to novel Rat parathyroid hormone 1-34 and the analogue of parathyroid hormone-related peptide, their solid phase synthesis and recombinant technology and they increase the purposes of sclerotin in Mammals.
B) description of correlative technology field
Osteoporosis is modal metabolic bone disease form, and can think Symptomatic, the fracture stage of bone forfeiture (osteopenia).Occur although osteoporosis can be secondary to many primary diseases, 90% case is idiopathic.Postmenopausal women especially easy idiopathic osteoporosis (after the menopause or I type osteoporosis).The height morbidity group of another spontaneous osteoporosis is people at advanced age (sex) (a senile or II type osteoporosis).Find that osteoporosis is relevant with following situation: use reflunomide, immobilization or CBR, excessive drinking, diabetes, to the chemotherapy of sexual gland virose (go-nadotoxic), blood prolactin too much, anorexia nervosa, primary and secondary amenorrhea and oophorectomize.
In various forms of osteoporosis, often to fracture, this is that the bone forfeiture reaches the result that the depleted point of mechanicalness is caused.The feature of post-menopausal osteoporosis is the fracture of wrist and backbone, and the fracture of the neck of femur principal character of senile osteoporosis seemingly.
The mechanism of bone forfeiture thinks to relate to the imbalance of bone self process in the osteoporosis.This renewal process is called as the bone remodeling process.This process is carried out in a series of various active bags.These bags seemingly are arranged on sclerotin and the certain bone surface as the bone resorption position spontaneously.Osteoclast (bone dissolving or absorptive cell) is responsible for absorbing the sclerotin of general constant big small portion.After this absorption process is scleroblast (bone forming cell) to occur, fills up the hole that osteoclast stays again by new sclerotin then.
In the grownup of health, osteoclast and osteoblastic formation speed are to make the process of bone forming and bone resorption be in equilibrium state.Yet the imbalance owing to the bone remodeling process in osteoporosis causes the speed of bone forfeiture faster than bone forming speed.All may have to a certain degree unbalance although increase with the age in most of people, at post-menopausal osteoporosis or this unbalance much serious after oophorectomize, and the age of appearance is littler.
The trial that many treatment osteoporosis aspect arranged is to slow down further bone forfeiture or more desirably make sclerotin have a net increase of length.Some medicament as oestrogenic hormon and diphosphate, can slow down the further forfeiture of sclerotin in the osteoporosis.Because bone resorption is different with osteoplastic period, as if can increase sclerotin (about 3-7%) so slow down the medicament of bone forfeiture.But this apparent growth is subjected to the restriction of time, is not progressive, and is that minimizing owing to " reinventing the space " causes.In addition, because be closely related between bone resorption and the formation, stop the treatment of bone resorption finally also can stop bone forming.
Existing people proposes, and treats with Rat parathyroid hormone 1-34 (PTH) can promote the bone turnover and cause positive calcium balance.But the human clinical trial shows that any increase of trabecular bone is offseted by the minimizing of cortical bone (cortical bone), does not therefore have the length that has a net increase of of total sclerotin.
Hefti, et al. is at Clinical Science 62, the middle report of 389-396 (1982) awards normal ash with the bPTH (1-84) of adult female rats subcutaneous dosage every day of suffering from osteoporosis or the calcareous and various bones that hPTH (1-34) can increase whole body and weighs.
Liu, et al. are at J.Bone Miner.Res.6:10, and 1071-1080 points out in (1991), can bring out nearly tibial metaphysis trabecular bone forfeiture 47% after the female rats spay of growing up, and the while is with the obvious increase of scleroblast and girder osteoclast number.Subcutaneous injection every day hPTH (1-34) thus the forfeiture that can reverse trabecular bone fully causes the quantity of trabecular bone to surpass the control group of simulated operation.Osteoblastic number increases and the number decline of osteoclast.
Hock et al. is at J.Bone Min.Res.7:1, and report among the 65-71 (1992) to healthy male rat subcutaneous injection every day hPTH (1-34) 12 days, causes the increase of the calcareous and dry weight of girder and cortical bone.Total sclerotin, trabecular bone volume, little cantilever thickness and number and scleroblast surface have all increased.
The Mammals Rat parathyroid hormone 1-34 as people's (hPTH), (bPTH) and (pTTH) of pig of ox, is the single polypeptide chain with 84 amino-acid residues, and molecular weight is about 9500.Biological activity is relevant in the N-terminal portions, and wherein residue (1-34) obviously is required minimum length.
The difference of the N-terminal fragment of the N-terminal fragment of people PTH and the hormone of ox and pig only has respectively 3 and 2 amino acid residue: hPTH (1-34) Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu1,5 10 15Asn Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp
20 25 30Val His Asn Phe (SEQ?ID?NO:1);bPTH(1-34):Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu1 5 10 15Ser Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp
20 25 30Val His Asn Phe (SEQ?ID?NO:2);pPTH(1-34)?:Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu1 5 10 15Ser Ser Leu Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp
20 25 30Val His Asn Phe (SEQ?ID?NO:3).
The major function of PTH is to cause adaptive variation, to keep Ca in the extracellular fluid
2+Constant density.PTH acts on kidney, increases uriniferous tubules to Ca in the urine
2+Heavily absorption, and stimulate 25-Hydroxy cholecalciferol to be transformed into 1, the 25-dihydroxycholecalciferol.This compound is responsible for Ca
2+Little intestinal absorption.A unusual effect is Ca in promoting bone
2+Move.When PTH acts on bone, increase Ca
2+With phosphatic absorption.PTH stimulates the bone resorption speed of osteoclast, increases the differentiation speed of mesenchymal cell to osteoclast, and the transformation period that prolongs osteoclast.Because the prolongation effect of PTH, osteoplastic osteoblastic number also increases; Therefore, the speed that has improved the bone turnover and reinvented.As if but each osteoblastic activity is lower than normal cell.
Rosenblatt, et al. be at U.S. patent No.4, discloses by disappearance N-end (1-6) amino acid in 423,037,4,968,669 and 5,001,223 and optionally replace Phe7, Met8,18 and Gly12 and the PTH antagonist that obtains.It is reported Tyr34-NH
2Can increase the active and stable of these compounds.
Parathyroid hormone-related peptide (PTHrp), a kind of more than 140 individual amino acid whose protein and fragment thereof can be simulated the main biological function of PTH.PTHrp can be synthetic by tumour and its hetero-organization of many humans and animals, and it can play a role in malignant hypercalcemia.The sequence of hPTHrp (1-34) is as follows: Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile1 5 10 15Gln Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu
20 25 30Ile His Thr Ala?(SEQ?ID?NO:4).
Sequence homology between hPTH and the hPTHrp mainly is confined to 13 N-terminal residues, and wherein 8 is identical; In the receptors bind zone of hPTH (25-34), have only 1 amino acid in hPTHrp, to guard in 10 amino acid.Comformational similarity may be to have common active reason.Cohen, et al. are at J.Biol.Chem.266:3, and 1997-2004 points out in (1991), most of sequence of PTH (1-34) and PTHrp (1-34), and especially zone (5-18) and (21-34) presents alpha-helix conformation.Simultaneously he also points out, whether this conformation is prevalent in that carboxyl terminal also has a question under the physiological condition.This secondary structure is vital for lipid interaction, acceptor interaction and/or structural stability.
We have synthesized the analogue of PTH and PTHrp so that develop therapeutical agent improvement, that be used for comprising the Mammals recovery sclerotin of suffering from osteoporosis.
Summary of the invention
The invention provides Rat parathyroid hormone 1-34 (PTH), parathyroid hormone-related peptide (PTHrp) and PTH and PTHrp and have the short homologue of physiologically active and the synthetic polypeptide analog and the salt thereof of analogue, wherein amino-acid residue (22-31) forms amphipathic alpha-helix, this residue (22-31) is selected from hydrophilic amino acid (the hy-drophilic amino acids by following series arrangement, Haa) and lipophilic amino-acid (lipophilic amino acids, Laa):
Haa(Laa?Laa?Haa?Haa)2Laa
When the concrete illustrative example of this sequence type inserts PTH, PTHrp, and PTH and PTHrp be when having the short homologue of physiologically active and analogue, the polypeptide of acquisition is effective bone remodeling agent.
On the one hand, the invention provides PTH, PTHrp and PTH and PTHrp and have the short homologue of physiologically active and analogue or its salt of analogue, wherein amino-acid residue (22-31) forms amphipathic alpha-helix, and the sequence of this residue (22-31) is selected from: a) Xaa
1Xaa
2Leu Xaa
4Xaa
5Leu Xaa
7Xaa
6Xaa
9Xaa
1015 10Xaa wherein
1And Xaa
4Be Glu independently of one another, Glu (OCH
3), His, or Phe; Xaa
2Be Leu or Phe; Xaa
5Be Lys or His; Xaa
7And Xaa
10Be Leu or Ile independently of one another; Xaa
8Be Ala, Arg, or Glu; And Xaa
9Be Lys or Glu (SEQ ID NO:26); B) Xaa
1Xaa
2Leu Xaa
4Arg Leu Leu Xaa
8Arg Leu is 15 10Xaa wherein
1And Xaa
4Be Glu independently of one another, Glu (OCH
3), His, or Phe; Xaa
2Be Leu or Phe; Xaa
8Be Glu, Lys, or Lys (COCH
2PEGX) and PEGX be that molecular weight is 100-10, poly-(Ethylene Glycol Methyl ether) residue (SEQ ID NO:27) of 000; C) Ala Leu Ala Glu Ala Leu Ala Glu Ala Leu (SEQ ID NO:28);
1 5 10d) Ser Leu Leu Ser Ser Leu Leu Ser Ser Leu (SEQ?ID?NO:29);
1 5 10e) Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu (SEQ?ID?NO:30).
1 5 10
On the other hand, the invention provides PTH, PTHrp with following formula structure and PTH and PTHrp and have the short homologue of physiologically active and the analogue or its salt: the Xaa of analogue
1Xaa
2Xaa
3Xaa
4Xaa
5Xaa
6Xaa
7Leu His Xaa
10Xaa
11Gly Xaa
13Ser Ile Gln Xaa
17Leu Xaa
19Xaa
20Xaa
21Xaa
22-31Xaa
32Xaa
33Xaa
34Xaa
35Xaa
36Xaa
37Xaa
38Term, wherein: Xaa
1Disappearance or Ala; Xaa
2Disappearance or Val; Xaa
3Disappearance or Ser; Xaa
4Disappearance or Glu or Glu (OCH
3); Xaa
5Disappearance or His or Ala; Xaa
6Disappearance or Gln; Xaa
7Disappearance or Leu; Xaa
10And Xaa
17Be Asp or Asp (OCH independently of one another
3); Xaa
11Be Lys, Arg, or Leu; Xaa
13Be Lys, Arg, Tyr, Cys, Leu, Cys (CH
2CONH (CH
2)
2NH (biotinyl)), Lys (7-dimethylamino-2-oxygen-2H-1-chromene-4-ethanoyl), or Lys (dihydro cinnamon acyl group); Xaa
20Be Arg or Leu; Xaa
19And Xaa
21Be Lys independently of one another, Ala, or Arg; Xaa
22-31Be selected from (SEQ ID NOS:26,27,28,29, or 30); Xaa
32Be His, Pro, or Lys; Xaa
33Disappearance, or Pro, Thr, Glu, or Ala; Xaa
34Disappearance, or Pro, Arg, Met, Ala, hSer, the hSer lactone, Tyr, Leu, or 1,4-diamino butyryl lactan; Xaa
35Disappearance or Pro, Glu, Ser, Ala, or Gly; Xaa
36Disappearance or Ala, Arg, or Ile; Xaa
37Disappearance or Arg, Trp, or 3-(2-naphthyl)-L-Ala; Xaa
38Disappearance or Ala or hSer or Xaa38-42 are Thr Arg Ser Ala Trp; With Term be OR or NR
2Wherein each R is H independently of one another, (C
1-C
4) alkyl or phenyl (C
1-C
4) alkyl; And pharmacy acceptable salt.
On the other hand, the invention provides PTH, PTHrp and PTH and PTHrp and have the short homologue of physiologically active and analogue or its salt of analogue, wherein amino-acid residue (22-31) forms amphipathic alpha-helix, and this residue (22-31) sequence is selected from: a) Glu Leu Leu Glu Lys Leu Leu Xaa Lys Leu wherein
15 10Xaa are Glu or Arg (SEQ ID NO:26); B) Glu Leu Leu Glu Arg Leu Leu Xaa Arg Leu wherein
15 10Xaa
29Be Glu, Lys, or Lys (COCH
2PEGX) and PEGX be that molecular weight is 100-10, poly-(Ethylene Glycol Methyl ether) residue (SEQ ID NO:27) of 000; C) Ala Leu Ala Glu Ala Leu Ala Glu Ala Leu (SEQ ID NO:28);
1 5 10d) Ser Leu Leu Ser Ser Leu Leu Ser Ser Leu (SEQ?ID?NO:29);
1 5 10e) Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu (SEQ?ID?NO:30).
1 5 10
The pharmaceutical composition that is used to prevent or treat the osteopenia situation also is provided, it comprises that Rat parathyroid hormone 1-34 (PTH), parathyroid hormone-related peptide (PTHrp) and the PTH and the PTHrp that add significant quantity with pharmaceutically acceptable carrier and hyperostosis have the short homologue of physiologically active and the polypeptide analog and the salt thereof of analogue, wherein amino-acid residue (22-31) forms amphipathic alpha-helix, and this residue (22-31) is selected from hydrophilic amino acid (Haa) and the lipophilic amino-acid (Laa) by following series arrangement:
Haa(Laa?Laa?Haa?Haa)
2?Laa.
The method of pharmaceutical compositions also is provided, and it comprises mixes above-claimed cpd mutually with pharmaceutically acceptable carrier.
In addition, the present invention also provides and has been used for the treatment of the method that the Mammals sclerotin reduces situation, this method comprises that adding PTH, the PTHrp of significant quantity and PTH and PTHrp to the administration hyperostosis of needs has the short homologue of physiologically active and polypeptide analog or its salt of analogue, wherein amino-acid residue (22-31) forms amphipathic alpha-helix, and this residue (22-31) is selected from hydrophilic amino acid (Haa) and the lipophilic amino-acid (Laa) by following series arrangement:
Haa(Laa?Laa?Haa?Haa)
2?Laa
More specifically, the invention provides and be used for the treatment of the method that the Mammals sclerotin reduces situation, this method comprises that adding PTH, the PTHrp of significant quantity and PTH and PTHrp to the administration hyperostosis of needs has the short homologue of physiologically active and polypeptide analog or its salt of analogue, wherein amino-acid residue (22-31) forms amphipathic alpha-helix, this residue (22-31) sequence is selected from: SEQ ID NO:26,27,28,29 and 30.
The present invention comprises that also PTH, PTHrp and PTH and PTHrp have the short homologue of physiologically active and the polypeptide analog of analogue, or the solid phase synthesis process of the salt of polypeptide analog, wherein amino-acid residue (22-31) forms amphipathic alpha-helix, and this residue (22-31) is selected from hydrophilic amino acid (Haa) and the lipophilic amino-acid (Laa) by following series arrangement:
Haa (Laa Laa Haa Haa)
2Laa, this method comprises in order that protected amino acid is coupled in the appropriate resin carrier, removes side chain and N
α-blocking group, and with polypeptide from resin separately.
The present invention comprises that also PTH, PTHrp and PTH and PTHrp have short homologue and the polypeptide analog of analogue or the solid phase synthesis process of its salt of physiologically active, wherein amino-acid residue (22-31) forms amphipathic alpha-helix, this residue (22-31) sequence is selected from: SEQ ID NO:26,27,28,29 and 30.This method comprises in order that protected amino acid is coupled in the appropriate resin carrier, removes side chain and N
α-blocking group, and with polypeptide from resin separately.
Also comprise PTH, PTHrp and PTH and PTHrp have the polypeptide analog of the short homologue of physiologically active and analogue or its salt the method that is re-combined into, wherein amino-acid residue (22-31) forms amphipathic alpha-helix, and this residue (22-31) is selected from hydrophilic amino acid (Haa) and the lipophilic amino-acid (Laa) by following series arrangement:
Haa(Laa?Laa?Haa?Haa)
2?Laa
The present invention also comprises dna sequence dna, carrier and the plasmid that is used to be re-combined into this polypeptide analog.Particularly, the invention provides and be used to be re-combined into short homologue and the polypeptide analog of analogue or dna sequence dna, carrier and the plasmid of its salt that PTH, PTHrp and PTH and PTHrp have physiologically active, wherein amino-acid residue (22-31) forms amphipathic alpha-helix, this residue (22-31) sequence is selected from: SEQ ID NO:26,27,28,29 and 30.
The accompanying drawing summary
Fig. 1 is the dna sequence dna and the restriction enzyme site (hPTH pcr amplification figure) of the synthetic gene of coding PTHrp of the present invention (1-34) analogue.
Fig. 2 has summarized the preparation (Trp LE 18 hPTHrp (1-34) 1 design of graphics) of the plasmid that is integrated with PTHrp (1-34) analogue gene.
Fig. 3 has summarized the preparation (Trp LE 18 hPTHrp (1-34) 2 design of graphics) of the plasmid that is integrated with two copy PTHrp (1-34) analogue genes.
Fig. 4 has summarized the preparation (Trp LE 18 hPTHrp (1-34) 4 design of graphics) of the plasmid that is integrated with 4 copy PTHrp (1-34) analogue genes.
Detailed Description Of The Invention
Abbreviation and definition
Press for various common nucleotide bases and amino acid whose monocase and three-character doctrine abbreviation Pure Appl.Chem.31,639-645 (1972) and 40,277-290 (1974) In advise and also meet 37 CFR § 1.822 (55FR 18245, May 1 nineteen ninety Day) and PCT rule (WIPO Standard ST.23:Recommendation for The Presentation of Nucleotide and Amino Acid Sequences in Patent APPlications and in Published Patent Documents). Monocase As follows with the three-character doctrine abbreviation: amino acid abbreviations
Amino acid three-character doctrine monocase
Alanine Ala A
Arginine Arg R
Asparagine Asn N
L-aminobutanedioic acid Asp D
Asn+Asp Asx B
Cysteine Cys C
Glutamine Gln Q
Glutamic acid Glu E
Gln+Glu Glx Z
Glycine Gly G
Histidine H
Isoleucine Ile I
Leucine Leu L
Lysine Lys K
Methionine Met M
Phenylalanine Phe F
Proline Pro P
Serine Ser S
Threonine Thr T
Tryptophan Trp W
Tyrosine Tyr Y
Valine Val V Abbreviation represents L-amino acid, unless in addition with D-or D, L-indicates. Some natural and non-natural Amino acid such as glycine are achiral. The method for expressing of all peptide sequences all is that the N-end is amino Acid is positioned at the left side and C-terminal amino acid is positioned at the right.
Other amino acid used herein and the abbreviation of compound are as follows:
The hSer homoserine
The hSerlac homoserine lactone
The Nle nor-leucine
The residue of PEG2 Diethylene Glycol methyl ether claims methoxyl group two (ethylene oxy again
Base), CH
3O (CH
2CH
2O)
2-, (molecular weight=119)
The residue of PEG5000 poly-(Ethylene Glycol Methyl ether) claims methoxyl group to gather (ethene again
The oxygen base), CH
3O (CH
2CH
2O)
110-, (molecular-weight average
=5000)
The residue of PEGX poly-(Ethylene Glycol Methyl ether), CH
3O
(CH
2CH
2O)
N-9, n=2-225, (molecular-weight average
=100-10,000)
" hydrophilic amino acid (Haa) " refers to except forming the required group of peptide bond, amino acid with at least one hydrophilic functional groups, for example arginine, amino-succinamic acid, Aspartic Acid, L-glutamic acid, glutamine, Histidine, Methionin, Serine, Threonine and homologue thereof.
" lipophilic amino-acid (Laa) " refers to uncharged, aliphatic series or aromatic amino acid, for example Isoleucine, leucine, methionine(Met), phenylalanine, tryptophane, tyrosine, Xie Ansuan and homologue thereof.
In the present invention, L-Ala is classified as " amphoteric amino acids ", and promptly it both can also can be used as lipophilic amino-acid as hydrophilic amino acid.
" PTH and PTHrp have the short homologue and the analogue of physiologically active " refer to have less than the corresponding sequence of amino acid of the total length of finding at PTH or PTHrp, but can cause the polypeptide of similar physiologic response.The PTH of brachymemma or PTHrp needn't could cause similar physiologic response with PTH or the complete homology of PTHrp.PTH (1-34) and PTHrp (1-34) are the preferred example in this group but do not get rid of other examples.
" amphipathic alpha-helix " refers to that amino acid takes the secondary structure that some polypeptide showed of alpha-helical conformation, and wherein the major axis along spiral has relative polarity and non-polar plane." Schiffer-Edmundson wheel " (M.Schiffer and the A.B.Edmundson that in interested polypeptide, exists the possibility of α-Luo Xuanjiegou can have suitable pitch to a certain extent by structure, Biophys.J.7,121 (1967)) and observe hydrophilic and lipophilic residue and whether separately be positioned at the circumscribed cylindrical opposite face of spiral and survey.Perhaps, also can for example garden dichroism or X ray diffracting data show have the alpha-helix zone in given polypeptide by the experimental evidence that obtains.The every circle of ideal alpha-helix has 3.6 amino acid, and wherein adjacent side chain is 100 degree separately.Eisenberg et al. in Nature 299:371-374 (1982) and Proc.Nat.Acad.Sci.USA 81:140-144 (1984) with hydrophobicity numerical value and spiral combination, quantitatively to determine the notion of amphipathic helix.Average hydrophobic square be defined as constituting spiral respectively form the hydrophobic vector of amino acid and.Eisen-berg (1984) is with the scale of following amino acid whose hydrophobicity as " consistence ": Ile 0.73; Phe 0.61; Val 0.54; Leu 0.53; Trp 0.37; Met 0.26; Ala 0.25; Gly 0.16; Cys 0.04; Tyr 0.02; Pro-0.07; Thr-0.18; Ser-0.26; His-0.40; Glu-0.62; Asn-0.64; Gln-0.69; Asp-0.72; Lys-1.10; Arg-1.76.
The hydrophobic square that has the desirable alpha-helix of 3.6 residues (being side chain 100 radians=(360 °/3.6) at interval) for every circle
μ H, can calculate with following formula:
μ H=[(Σ H
NSin δ (N-1)) 2+ (Σ H
NCos δ (N-1)) 2]
1/2, wherein, H
NBe N
ThAmino acid whose hydrophobicity value, and and be in the sequence of frequency δ=100 ° N amino acid whose and.Hydrophobic square can be used μ
HMerchant<the μ that obtains divided by N
HBe expressed as the average hydrophobic square of each residue.In 100 ° ± 20 ° scopes<μ
HValue for about 0.20 or bigger just expression have amphipathic helix.For hPTHrp (22-31) and hPTH (22-31), 100 °<μ
HValue is respectively 0.19 and 0.37.
Cornett, et al. at J.Mol.Biol., has further expanded the research of amphipathic alpha-helix among the 195:659-685 (1987), introduced " amphipathic index " as amphipathic predictor.They reach a conclusion, and it is amphipathic that half all known alpha-helix is arranged approximately, and main frequency is 97.5 ° rather than 100 °, and the residue number of every circle is more near 3.7 rather than 3.6.Although this levels of precision is interesting on science, people's such as Eisenberg basic skills has been used for enough determining whether given sequence is amphipathic, especially starts anew implementation sequence when forming amphipathic alpha-helix as people.
The amphipathic alpha-helix aminoacid sequence that replaces can be not and the given fragment sequence homology of naturally occurring polypeptide, but should have similar secondary structure under physiological status, promptly has the relative polarity and the alpha-helix of non-polar plane.Replace naturally occurring aminoacid sequence with other sequences and may produce favorable influence for physiologically active, stability or other performances of the parent polypeptide that changes.At J.L.Krstenansky, et al., FEBS Letters 242:2,409-413 (1989), and J.P.Segrest, et al.Proteins:Structure, the guidance that designs and select this sequence aspect is arranged among Function and the Genetics 8:103-117 (1990) etc.
10 amino acid whose amphipathic alpha-helixs of the present invention have following formula:
Haa (Laa Laa Haa Haa)
2Laa wherein, Haa is selected from hydrophilic amino acid as mentioned above, and Laa is selected from above-mentioned lipophilic amino-acid.Suppose the ideal alpha-helix, residue 1,4,5,8 and 9 are distributed on the face (A) of spiral, and within about each other 140 °, and residue 2,3,6,7 and 10 occupy 140 ° of another side (B) of spiral.Preferably, all residues that are positioned at one side all are identical polars, and all residues that are positioned at another side all are opposite polarities, if promptly the A face all is hydrophilic, the B face all is lipophilic so, and vice versa.Those of skill in the art know, although spiral of the present invention is to use
Haa (Laa Laa Haa Haa)
2Laa represents, but opposite sequence
Laa (Haa Haa Laa Laa)
2Therefore Haa also meets residue distribution standard, is the describing mode that the another kind of spiral of the present invention is equal to.
L-Ala can replace hydrophilic amino acid or lipophilic amino-acid, because L-Ala can be positioned at any one side of amphipathic alpha-helix without difficulty, although Ala
10Can not form amphipathic alpha-helix.Generally speaking, do not use proline(Pro), halfcystine and tyrosine; Their existence and other random errors can be tolerated in sequence, for example have hydrophilic residue at the lipophilic face, as long as all the other amino acid in the fragment meet the division of hydrophilic-lipophilic face on substantially.Be used for determining that thereby whether a certain sequence has enough amphipathic short-cut methods that can become sequence of the present invention is to calculate its average hydrophobic square as mentioned above.If the average square peak value of each residue surpasses approximately 0.20 in 100 ° ± 20 ° scopes, this sequence can form amphipathic helix and be sequence of the present invention so.
For example, for SEQ ID NO:26, Xaa=Glu, being calculated as follows of 100 ° of average hydrophobic squares of locating each residue: A.A.H
Nδ (N-1) H sinδ (N-1) H cosδ (N-1)E -.62 0 0 -.62L .53 100 .52 -.17L .53 200 -.18 -.50E -.62 300 .34 -.31K -1.1 400 -.70 -.85L .53 500 .34 -.41L .53 600 -.46 -.27E -.62 700 .21 -.58K -1.1 800 -1.08 -.19L .53 900 0 -.53
∑=0.81?Σ=-4.43
μ
H=[(0.81)
2+(-4.43)
2]
1/2=4.50
<μ
H>=4.50/10=0.45
For this sequence, the peak value of average hydrophobic square appears at 92 °, and its value is 0.48.
When this notion is applied to Rat parathyroid hormone 1-34 and parathyroid hormone-related peptide, can suppose zone (7-16) and (22-31) in a zone or two zones have the alpha-helix secondary structure, and can be with non-homogeneous sequence displacement with similar structures tendency can loss of biological activity or the performance of induction of immunity reaction.Preferred example
On the one hand, the invention provides PTH, PTHrp and PTH and PTHrp and have the short homologue of physiologically active and analogue or its salt of analogue, wherein amino-acid residue (22-31) forms amphipathic alpha-helix, and this residue (22-31) sequence is selected from: a) Xaa
1Xaa
2Leu Xaa
4Xaa
5Leu Xaa
7Xaa
8Xaa
9Xaa
10Wherein
15 10Xaa
1And Xaa
4Be Glu independently of one another, Glu (OCH
3), His, or Phe; Xaa
2Be Leu or Phe; Xaa
5Be Lys or His; Xaa
7And Xaa
10Be Leu or Ile independently of one another; Xaa
8Be Ala, Arg, or Glu; And Xaa
9Be Lys or Glu (SEQ ID NO:26); B) Xaa
1Xaa
2Leu Xaa
4Arg Leu Leu Xaa
8Arg Leu wherein
15 10Xaa
1And Xaa
4Be Glu independently of one another, Glu (OCH
3), His, or Phe; Xaa
2Be Leu or Phe; Xaa
8Be Glu, Lys, or Lys (COCH
2PEGX) and PEGX be that molecular weight is 100-10, poly-(Ethylene Glycol Methyl ether) residue (SEQ ID NO:27) of 000; C) Ala Leu Ala Glu Ala Leu Ala Glu Ala Leu (SEQ ID NO:28);
1 5 10d) Ser Leu Leu Ser Ser Leu Leu Ser Ser Leu (SEQ?ID?NO:29);
1 5 10e) Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu (SEQ?ID?NO:30).
1 5 10
On the other hand, the invention provides PTH, PTHrp with following formula structure and PTH and PTHrp and have the short homologue of physiologically active and the analogue or its salt: the Xaa of analogue
1Xaa
2Xaa
3Xaa
4Xaa
5Xaa
6Xaa
7Leu His Xaa
10Xaa
11Gly Xaa
13Ser Ile Gln Xaa
17Leu Xaa
19Xaa
20Xaa
21Xaa
22-31Xaa
32Xaa
33Xaa
34Xaa
35Xaa
36Xaa
37Xaa
38Term, wherein: Xaa
1Disappearance or Ala; Xaa
2Disappearance or Val; Xaa
3Disappearance or Ser; Xaa
4Disappearance or Glu or Glu (OCH
3); Xaa
5Disappearance or His or Ala; Xaa
6Disappearance or Gln; Xaa
7Disappearance or Leu; Xaa
10And Xaa
17Be Asp or Asp (OCH independently of one another
3); Xaa
11Be Lys, Arg, or Leu; Xaa
13Be Lys, Arg, Tyr, Cys, Leu, Cys (CH
2CONH (CH
2)
2NH (biotinyl)), Lys (7-dimethylamino-2-oxygen-2H-1-chromene-4-ethanoyl), or Lys (dihydro cinnamon acyl group); Xaa
20Be Arg or Leu; Xaa
19And Xaa
21Be Lys independently of one another, Ala, or Arg; Xaa
22-31Be selected from (SEQ ID NOS:26,27,28,29, or 30); Xaa
32Be His, Pro, or Lys; Xaa
33Disappearance, or Pro, Thr, Glu, or Ala; Xaa
34Disappearance, or Pro, Arg, Met, Ala, hSer, the hSer lactone, Tyr, Leu, or 1,4-diamino butyryl lactan; Xaa
35Disappearance or Pro, Glu, Ser, Ala, or Gly; Xaa
36Disappearance or Ala, Arg, or Ile; Xaa
37Disappearance or Arg, Trp, or 3-(2-naphthyl)-L-Ala; Xaa
38Disappearance or Ala or hSer or Xaa
38-42Be Thr Arg Ser Ala Trp; With Term be OR or NR
2Wherein each R is H independently of one another, (C
1-C
4) alkyl or phenyl (C
1-C
4) alkyl; And pharmacy acceptable salt.
On the other hand, the present invention includes the polypeptide analog of the short homologue of hPTHrp shown in formula I, that have physiologically active (1-34): Ala Val Ser Glu Xaa
5Gln Leu Leu His Asp Xaa
11Gly Xaa
13Ser IleGln Asp Leu Xaa
19Arg Xaa
21Xaa
22-31Xaa
32Xaa
33Xaa
34Term, wherein: Xaa
5Be His or Ala; Xaa
11And Xaa
13Be Lys independently of one another, Arg, or Leu; Xaa
19And Xaa
21Be Ala or Arg independently of one another; Xaa
22-31Be selected from: a) Glu Leu Leu Glu Lys Leu Leu Xaa Lys Leu wherein
15 10Xaa are Glu or Arg (SEQ ID NO:26); B) Glu Leu Leu Glu Arg Leu Leu Xaa Arg Leu wherein
15 10Xaa are Glu, Lys, or Lys (COCH
2PEGX) and PEGX be that molecular weight is 100-10, poly-(Ethylene Glycol Methyl ether) residue (SEQ ID NO:27) of 000; C) Ala Leu Ala Glu Ala Leu Ala Glu Ala Leu (SEQ ID NO:28);
1 5 10d) Ser Leu Leu Ser Ser Leu Leu Ser Ser Leu (SEQ?ID?NO:29);
1 5 10e) Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu (SEQ?ID?NO:30);
15 10Xaa
32Be His or Lys; Xaa
33Be Thr, Glu, or Ala; Xaa
34Be Ala, hSer, Tyr, or Leu; With Term be Gly Arg Arg, lactone, OH or NR
2, wherein each R is H or (C
1-C
4) alkyl; And pharmacy acceptable salt (formula I).
Another concrete aspect of the present invention comprises Xaa
22-31Be the formula I polypeptide of (SEQ ID NO:26), these polypeptide 100 °<μ
HSurpass 0.45.Of the present invention one more specifically the aspect comprise Xaa
22-31Be (SEQ ID NO:26), Xaa
11And Xaa
13All be Lys and Xaa
19And Xaa
21It all is the formula I polypeptide of Arg.
Representational polypeptide comprises, but is not limited to: Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile1 5 10 15Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Arg Lys
20 25 30Leu His Thr Ala OH (SEQ?ID?NO:5);Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile1 5 10 15Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys
20 25 30Leu His Thr Ala OH (SEQ?ID?NO:6);Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile1 5 10 15Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys
20 25 30Leu His Thr Ala NH2 (SEQ?ID?NO:7);Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile1 5 10 15Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys
20 25 30Leu His Thr hSer NH2 (SEQ?ID?NO:8);Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile1 5 10 15Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys
20 25 30Leu His Thr hSerlac (SEQ?ID?NO:9);Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile1 5 10 15Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys
20 25 30Leu His Thr Ala Gly Arg Arg OH (SEQ ID NO:10); With 35Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser lle1 5 10 15Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys
20 25 30Leu Lys Glu Leu NH
2 (SEQ?ID?NO:11).
Another aspect of the present invention comprises Xaa
22-31Be (SEQ ID NO:26), Xaa
11And Xaa
13All be Lys and Xaa
19And Xaa
21In one for Arg another is the formula I polypeptide of Ala.The representational polypeptide of this subclass comprises, but is not limited to: Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile1 5 10 15Gln Asp Leu Ala Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys
20 25 30Leu His Thr Ala NH2 (SEQ ID NO:12) and Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile1 5 10 15Gln Asp Leu Arg Arg Ala Glu Leu Leu Glu Lys Leu Leu Glu Lys
20 25 30Leu His Thr Ala NH
2 (SEQ?ID?NO:13).
Another concrete aspect of the present invention comprises Xaa
22-31Be (SEQ ID NO:26), Xaa
11And Xaa
13In one for Leu another is Lys and Xaa
19And Xaa
21It all is the formula I polypeptide of Arg.The representational polypeptide of this subclass comprises, but is not limited to: Ala Val Ser Glu Ala Gln Leu Leu His Asp Leu Gly Lys Ser Ile1 5 10 15Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys
20 25 30Leu His Ala Leu OH (SEQ?ID?NO:14).
Another concrete aspect of the present invention comprises Xaa
22-31Be the formula I polypeptide of (SEQ ID NO:27), these polypeptide 100 °<μ
HSurpass 0.50.Further aspect of the present invention comprises Xaa
22-31Be (SEQ ID NO:27), Xaa
11And Xaa
13All be Lys or all be Arg and Xaa
19And Xaa
21It all is the formula I polypeptide of Arg.The representational polypeptide of this subclass comprises, but is not limited to: Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile1 5 10 15Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Arg Leu Leu Glu Arg
20 25 30Leu His Thr Ala OH (SEQ?ID?NO:15);Ala Val Ser Glu His Gln Leu Leu His Asp Arg Gly Arg Ser Ile1 5 10 15Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Arg Leu Leu Glu Arg
20 25 30Leu His Thr Ala OH (SEQ?ID?NO:16);Ala Val Ser Glu His Gln Leu Leu His Asp Arg Gly Arg Ser Ile1 5 10 15Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Arg Leu Leu Lys Arg
20 25 30Leu His Thr Ala OH (SEQ?ID?NO:17);Ala Val Ser Glu His Gln Leu Leu His Asp Arg Gly Arg Ser Ile1 5 10 15Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Arg Leu Leu
20 25Lys (COCH:PEG2) Arg Leu His Thr Ala OH (SEQ ID NO:18); With
30Ala Val Ser Glu His Gln Leu Leu His Asp Arg Gly Arg Ser Ile1 5 10 15Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Arg Leu Leu
20 25Lys(COCH:PEG5000) Arg Leu His Thr Ala OH (SEQ?ID?NO:19).
30
Another concrete aspect of the present invention comprises Xaa
22-31Be the formula I polypeptide of (SEQ ID NO:28), these polypeptide 100 °<μ
HBe about 0.25.The representational polypeptide of this subclass comprises, but is not limited to: Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile1 5 10 15 Gln Asp Leu Arg Arg Arg Ala Leu Ala Glu Ala Leu Ala Glu Ala
20 25 30Leu His Thr Ala NH2 (SEQ?ID?NO:20).
Another concrete aspect of the present invention comprises Xaa
22-31Be the formula I polypeptide of (SEQ ID NO:29), these polypeptide 100 °<μ
HBe about 0.28.The representational polypeptide of this subclass comprises, but is not limited to: Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile1 5 10 15Gln Asp Leu Arg Arg Arg Ser Leu Leu Ser Ser Leu Leu Ser Ser
20 25 30Leu His Thr Ala NH (SEQ?ID?NO:21).
Another concrete aspect of the present invention comprises Xaa
22-31Be the formula I polypeptide of (SEQ ID NO:30), these polypeptide 100 °<μ
HBe about 0.29.The representational polypeptide of this subclass comprises, but is not limited to: Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile1 5 10 15Gln Asp Leu Arg Arg Arg Ala Phe Tyr Asp Lys Val Ala Glu Lys
20 25 30Leu His Thr Ala NH2 (SEQ?ID?NO:22).
Another aspect of the present invention comprises the polypeptide analog of the short homologue of bPTH shown in formula II, that have physiologically active (1-34): Xaa
1Val Ser Glu Ile Gln Xaa
7Xaa
8His Asn Leu Gly Lys His LeuXaa
15Ser Xaa
18Xaa
19Arg Xaa
21Xaa
22-31His Asn Xaa
34Term, wherein: Xaa
1Be Ser or Ala; Xaa
7Be Leu or Phe; Xaa
8Be Met or Nle; Xaa
16Be Asn or Ser; Xaa
18Be Leu, Met, or Nle; Xaa
19Be Glu or Arg; Xaa
21Be Val or Arg; Xaa
22-31Be selected from (SEQ ID NO:26,27,28,29 and 30); Xaa
34Be Phe or Tyr; Term is OH or NR
2, wherein each R is H or (C
1-C
4) alkyl; And pharmacy acceptable salt (formula II).Representational polypeptide comprises, but is not limited to: Ala Val Ser Glu Ile Gln Phe Nle His Asn Leu Gly Lys His Leu1 5 10 15Ser Ser Nle Glu Arg Val Glu Leu Leu Glu Lys Leu Leu Glu Lys
20 25 30Leu His Asn Tyr NHz (SEQ ID NO:23) and Ala Val Ser Glu Ile Gln Phe Nle His Asn Leu Gly Lys His Leu1 5 10 15Ser Ser Nle Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys
20 25 30Leu His Asn Tyr NH2 (SEQ?ID?NO:24).
In still another aspect of the invention, be surprised to find, the homologue and the analogue that are less than 34 amino acid whose PTH and PTHrp also are effective bone remodeling agent.These compounds have following general formula: Ala Val Ser Glu Xaa
5Gln Leu Leu His Asp Xaa
11Gly Xaa
13Ser IleGln Asp Leu Xaa
19Arg Xaa
21Xaa
22-31Xaa
32Xaa
33Xaa
34Term, representational polypeptide comprises, but is not limited to: compound 41:AVSEHQLLHD KGKSIQDLRR RELLEKLLEKLHP-NH2 (SEQ ID NO:55) physical data m.p.142.8-166.1 ℃ [α]
25 D-53.80 (c 0.38, H
2O) FAB (C
173H
295N
55O
9): [M+H]
+3929AAA:AsX2.0 (2) Glx5.7 (6) Ser1.8 (2)
His3.0(3)Gly1.1(1)Ala0.9(1)
Arg2.8(3)Val1.2(1)Ile0.9(1)
Leu7.4 (8) Lys4.4 (4) Pro0.9 (1) compound 42:AVSEHQLLHD KGKSIQDLRR RELLEKLLEK LP-NH2 (SEQ ID NO:56) physical data m.p.161.0-177.0 ℃ [α]
25 D-61.97 (c 0.19, H
2O) FAB (C
167H
88N
52O
48): [M+H]
+3792.0AAA:Asx2.2 (2) Glx5.9 (6) Serl.9 (2)
His2.1(2)Gly1.1(1)Ala1.0(1)
Arg3.0(3)Val1.1(1)Ile1.0(1)
Leu7.9(8)Lys4.3(4)Pro0.9(1)
Those of skill in the art know, can synthesize changing form of a large amount of polypeptide analogs.These change form and have the useful performance of analogue described herein, if will be in 100 ° ± 20 ° scopes the average hydrophobic square of each residue greater than about 0.20 aminoacid sequence on position (22-31).The classics of polypeptide are synthetic
Polypeptide of the present invention can use-case such as following method synthetic: J.M.Stewart and J.D.Young, Solid Phase Peptide Synthesis, 2nd ed., PierceChemical Co., Rockford, Illinois (1 984) and J.Meienhofer, Hor-monal Proteins and Peptides, Vol.2, Academic Press, NewYork, solid phase synthesis and the E.Schroder and the K.Lubke of (1973) etc., ThePeptides, Vol.l, Academic Press, New York, the solution of (1965) etc. is synthetic.
Generally, the peptide chain that relates in synthetic of these methods adds protected amino acid successively.Usually, first amino acid whose amino or carboxyl and all reactive side chains are all protected.Then the amino acid with protection is connected in inert solid carrier, perhaps is used for solution, adds by the next amino acid in the sequence of due care under the condition that is fit to the formation amido linkage then.After all required amino acid all link to each other with suitable sequence, thereby remove blocking group and solid carrier obtains thick polypeptide.This polypeptide is through desalination and purifying (preferably passing through chromatography), thus the acquisition the finished product.
A kind of preparation is that solid-phase polypeptide synthesizes less than about 40 preferred method amino acid whose, short polypeptide with physiologically active.In the method, a-amino acid (N
α) functional group and any reactive side chain all uses acid-sensitive or alkali is quick (acid-or base-sensitive) radical protection.Blocking group should be stable forming under the condition of peptide bond, can be removed without difficulty again simultaneously and does not influence established polypeptide chain.Suitable alpha-amino group blocking group comprises; but be not limited to: uncle-butoxy carbonyl (Boc), benzyloxycarbonyl (Cbz), neighbour-chlorine benzyloxycarbonyl, phenylbenzene isopropoxy carbonyl, uncle-pentyloxy carbonyl (Amoc), iso-borneol oxygen base (isoborny-loxy) carbonyl, α; alpha-alpha-dimethyl-3,5-dimethoxy benzyloxy-carbonyl, o-nitrophenyl sulfinyl (nitrophenylsulfenyl), 2-cyano group-uncle-butoxy carbonyl, 9-fluorenyl methoxy carbonyl (Fmoc) etc., preferred tertiary-butoxy carbonyl (Boc).Suitable side chain protected group comprises; but be not limited to: ethanoyl, benzyl (Bzl), benzyloxymethyl (Bom), neighbour-bromo-benzyloxy-carbonyl, tert-butyl, tert-butyl dimetylsilyl, 2-benzyl chloride base (Cl-z), 2,6-dichloro benzyl, cyclohexyl, cyclopentyl, sec.-propyl, valeryl, tetrahydropyrans-2-base, tosyl group (Tos), trimethyl silyl and trityl.
In solid phase synthesis, the C-end amino acid at first is connected in the appropriate resin carrier.To be those be inertia and be insoluble to used medium progressively condensation reaction and the reagent in the protective reaction and reaction conditions the appropriate resin carrier.The example of commercially available resin comprises the vinylbenzene/divinylbenzene resin with the active group modification, for example copolymerization of chloromethylation (vinylbenzene-Vinylstyrene), methylolated copolymerization (vinylbenzene-Vinylstyrene) etc.Preferred benzylization, methylolated phenyl-acetamides methyl (PAM) resin.When the C-terminal of compound was acid amides, preferred resin was right-methyldiphenyl methylamino-copolymerization (vinylbenzene-Vinylstyrene) resin.
Can be by at ethanol, acetonitrile, N, in the dinethylformamide (DMF) etc. as ammonium salt, cesium salt, triethyl ammonium salt, 1,5-diazabicylo [5.4.0] 11 carbon-5-alkene, the N that tetramethyl ammonium or class are saloid (preferably being arranged in the cesium salt of DMF)
aThe amino acid of protection, preferred Boc-amino acid, with resin 40-60 ℃ according to appointment of high temperature, be preferably about 50 ℃ of reactions about 12-72 hour down, preferable about 48 hours, and it is connected in the PAM resin.
Can be as methylene dichloride or dimethyl formamide, be preferably in the solvent of methylene dichloride and so on, by as N, the coupling reaction of N '-di-isopropyl carbodiimide (DIC)/l-hydroxybenzotriazole (HOBt) mediation, at about 10-50 ℃, be preferably about 25 ℃, reacted about 2-24 hour, be preferably about 2 hours and N
a-Boc-amino acid is connected in benzhydrylamine resin.
The continuous coupled of protected amino-acid subsequently can be carried out with method well known in the art, typically by the automatic peptide synthesizer.After with triethylamine or similar alkali neutralization; be preferably the every kind of protection amino acid that adds about 1.5-2.5 times molar excess, and coupling reaction is to carry out under room temperature in inert, nonaqueous, polar solvent such as methylene dichloride, DMF or its compound (preferably methylene dichloride).Representational coupling agent is N; N '-dicyclohexyl carbodiimide (DCC), N; N '-di-isopropyl carbodiimide (DIC) or other carbodiimide, they can use separately or use in the presence of I-hydroxybenzotriazole (HOBt), O-acylurea, phosphofluoric acid benzotriazole-1-base-oxo three (pyrrolidyl)-Phosphonium (PyBop), N-hydroxy-succinamide, other N-hydroxyl imides or oxime.Also can use shielded amino acid whose active ester (for example right-nitrophenyl, pentafluorophenyl group etc.) or symmetric acid anhydrides.
Last at solid phase synthesis removed the peptide of full guard from resin.When the key that links to each other with resin carrier is benzyl ester type,, can carries out ammonolysis reaction and reach cracking with alkylamine or fluoro-alkyl amine for peptide with alkylamide C-end; For peptide with unsubstituted acid amides C-end, can carry out ammonolysis reaction and reach cracking with for example ammonia/methyl alcohol or ammonia/ethanol, these reactions can be between approximately-10 ℃ and 50 ℃, are preferably under about 25 ℃ about 12-24 hour, are preferably about 18 ℃.Peptide with hydroxyl C-end can go protected mode or the cracking by saponification reaction with HF cracking cut-out or with other strongly-acids.Perhaps, can remove peptide from resin, for example carry out transesterificationization, and then separate or saponification is carried out by ammonia with methyl alcohol by transesterificationization.Protected peptide can pass through the silica gel chromatography purifying.
Can use following method that the side chain protected group is removed from peptide: in the presence of methyl-phenoxide or other carbon ion scavenging agents, to handle the ammonia hydrolysis products with for example anhydrous liquid hydrogen fluoride; handle with hydrogen fluoride/pyridine mixture; handle with three (trifluoroacetyl group) boron and trifluoroacetic acid; reduce with palladium on hydrogen and the carbon or Polyvinylpyrolidone (PVP); perhaps reduce, preferably handle with liquid hydrogen fluoride and methyl-phenoxide with the sodium in the liquid ammonia.These reactions are that preferable about 0 ℃ was carried out about 15 minutes to 2 hours, and was preferably about 1.5 hours between about-10 ℃ and 10 ℃.
For the peptide on benzhydrylamine resin, scission reaction and go to protect step to merge into a step from the resin with above-mentioned liquid hydrogen fluoride and methyl-phenoxide.
Solution can desalination (for example be used BioRad AG-3
_Anionite-exchange resin), and peptide can be with one or more carry out a series of chromatographic step and are able to purifying in the following method: on weakly alkaline acetate form resin, carry out ion-exchange; At the copolymerization (vinylbenzene-Vinylstyrene) of non-derivative type Amberlite for example
_Carry out hydrophobic adsorption chromatography on the XAD; Silica gel adsorption chromatography; On carboxymethyl cellulose, carry out ion-exchange chromatography; At for example Sephadex
_Carry out distribution chromatography on the G-25; Adverse current is distributed; Or high performance liquid chromatography (HPLC), especially octyl group-or octadecyl silyl silicon oxide (ODS) bonding phase column on reverse high performance liquid chromatography.
Therefore; the present invention relates to the method for preparing polypeptide and pharmacy acceptable salt thereof on the other hand; these methods are included on the appropriate resin carrier amino acid of the protection of condensation successively; remove blocking group and resin carrier; and thereby purified product obtains PTH and PTHrp has the short homologue of physiologically active and the analogue of analogue, especially H (1-34) and PTHrp (1-34), and the amino acid that wherein is positioned at position (22-31) forms aforesaid amphipathic alpha-helix peptide sequence.Being re-combined into of polypeptide
In addition, the preparation of polypeptide of the present invention also can be by cloning and express the encoding gene of required polypeptide.In the method, preparation contains the plasmid of required dna sequence dna, is inserted into the appropriate host microorganism then, typically is bacterium such as intestinal bacteria, or yeast such as yeast saccharomyces cerevisiae.Induce host microorganism to produce the code cDNA of the polypeptide analog of the present invention of the plasmid of multiple copied and multiple copied.
At first, the synthetic gene coding of the selected PTH or PTHrp of design is assisted subsequently change with easy restriction enzyme site.Can use Mullis at U.S. patent No.4,683,195 and 4,683, the polymerase chain reaction described in 202 (PCR) comes sequence spreading.
Separate the synthetic gene of expansion then and it is connected in suitable plasmid, Trp LE plasmid for example can tandem ground in this plasmid inserts the gene of 4 copies.The preparation of Trp LE plasmid is in U.S. Patent No. 4,738,921 and European patent publication No.0212532 in description is arranged.Trp LE plasmid produces the protein that 8-10 manys times than Trp E plasmid usually.Multi-copy gene can be as expressing in intestinal bacteria or the yeast saccharomyces cerevisiae in appropriate host then.
Use herein embody carrier be the Trp LE18 Prot that contains the following units (Ile3, Pro5): the pBR322 fragment (EcoR I-BamH I) that contains ampicillin resistance gene and plasmid replication starting point; EcoR I-Sac II the fragment that contains trp promotor and trpE gene; Hiv protease (Ile3, Pro5) gene fragment (Sac II-Hind III); BGRF gene fragment (Hind III-BamH I); With from intestinal bacteria rpoc gene transcription terminator.Hiv protease and bGRF gene fragment are not vital, can be replaced by other encoding sequences if desired.
The fusion protein polymer of expressing gathers in the inclusion body of cell inner stablity, can itself and other cell proteins be separated by centrifugal.Isolating protein then is transformed into monomer PTH or PTHrp analogue, and can carry out purifying with cationic exchange and/or reverse hplc.
For those skilled in the art, other clone, expansion, expression and purification process are conspicuous.Representational method is disclosed in Maniatis, et al., and MolecularCloning, A LaboratoryManual, 2nd Ed. is among the Cold Spring HarborLaboratory (1989).Use and use
Polypeptide of the present invention can be used for prevention and treat various Mammals sclerotin forfeiture symptoms.Especially, shown that compound of the present invention can be used to prevent and treat as therapeutical agent people's osteoporosis and osteopenia.
Usually, the amount of application of polypeptide of the present invention or its salt is about 0.002-1 microgram/kg body weight every day, is preferably about 0.04-0.2 microgram/kg body weight every day.For the women of one 50 kg body weight, the activeconstituents dosage of every day is about 0.1-50 microgram, is preferably about 2.0-10 microgram.For other Mammals, for example horse, dog and ox need higher dosage.This dosage can be with the pharmaceutical compositions of routine, thus on demand by single administration, by repeatedly using or supplying medicine to reach best drug effect by controlled release forms, wherein preferably inject one or many every day.
The selection of precise dosage and composition and best dosage regimen is subjected to the influence of many factors, particularly: the pharmacological properties of selected polypeptide, the character of illness to be treated and severity and patient's physical appearance and mental acuity (mental acuity).
Representational dosage regimen comprises: oral, parenteral admin (comprising subcutaneous, intramuscular and intravenous injection), rectal administration, orally administering (comprising sublingual administration), pulmonary administration, through skin and intranasal administration.
Pharmacy acceptable salt has kept the useful biological activity of former polypeptide and has not produced toxic side effect.The example of this salt is: (a) acid salt that forms with mineral acid example hydrochloric acid, Hydrogen bromide, sulfuric acid, phosphoric acid, nitric acid etc.; The salt that forms with organic acid such as acetate, oxalic acid, tartrate, succsinic acid, toxilic acid, fumaric acid, glyconic acid, citric acid, oxysuccinic acid, xitix, phenylformic acid, Weibull, pamoic acid, alginic acid, polyglutamic acid, naphthene sulfonic acid, naphthalene disulfonic acid, polygalacturonic acid etc.; (b) with multivalent metal cation such as zinc, calcium, bismuth, barium, magnesium, aluminium, copper, cobalt, nickel, cadmium etc., or and N, the base addition salt that the organic cation that N '-dibenzyl-ethylenediamin or quadrol form forms; Or (c) (a) and combining form (b) such as Weibull zinc salt etc.
Another aspect of the present invention relates to pharmaceutical composition, and they contain polypeptide of the present invention or its pharmacy acceptable salt as active constituent and pharmaceutically acceptable, nontoxic carrier.As mentioned above, this composition of preparation can be used for parenteral admin (subcutaneous, intramuscular and intravenous injection), especially with liquid solution or suspension form; Be used for oral or orally administering, especially with tablet or capsule combinate form formula; Be used for lung and intranasal administration, especially with pulvis, nasal drop or aerosol form; And be used for rectum or percutaneous dosing.
Composition can be used with presented in unit dosage form easily, and can be prepared with any method of knowing in the pharmacy field, for example at Remington ' s PharmaceuticalSciences, 17th ed., Mack Publishing Company, Easton, PA., the method described in (1985).For the prescription of parenteral admin, can contain sterilized water or physiological saline, aklylene glycol (alkylene glycols) as propylene glycol, poly-alkylene glycol such as polyoxyethylene glycol, vegetables oil, hydrogenated naphthalene etc. as vehicle.For oral administration, prescription can increase drug effect by adding cholate or fatty acyl carnitine.The preparation that is used for intranasal administration can be solid and contain vehicle for example lactose or dextran, perhaps can be that water-based or oily solution are used with the form of nasal drop or metering spray agent.For orally administering, typical vehicle comprises sugar, calcium stearate, Magnesium Stearate, pregelatinized starch etc.
When preparing for intranasal administration; can be by adding for example increase Nasal Mucosa Absorption such as paddy ammonia cholic acid, cholic acid, taurocholate, second cholic acid (ethocholic acid), Septochol, gallodesoxycholic acid, Felacrinos, paddy ammonia Septochol, cyclodextrin of acid surface active agent; addition is about the 0.2-15 weight percent; be preferably about 0.5-4 weight percent, the best is about 2 weight percents.
Controlled release system by containing q.s effective constituent (for required release period) single-dose can be in long-time for example one be supplied with the pill taker with compound of the present invention in thoughtful 1 year.Various controlled release systems are individual layer or depot micro-capsule, depot implant, osmotic pump, vesica, capsule, liposome, transdermal patch for example, and iontophoresis device and other injection types may be used to this purpose.To be confined to need the position of active constituent be another feature of some controlled release drug administration device with using, and this is favourable for some disease of treatment.
A kind of controlled release preparation disperses polypeptide or its salt or is wrapped in slow degraded, nontoxic, nonantigenic polymkeric substance such as the copolymerization (lactic acid/oxyacetic acid), as at Kent, and Lewis, Sanders, with described in the work initiative in the United States Patent (USP) 4,675,189 of Tice like that.Also compound or better its insoluble relatively salt can be formulated in cholesterol or other lipid matrix pillers, or in the silastomer matrix implant.Other sustained release dosage, depot implant or injectable formulation are that those of skill in the art are known.Referring to for example, Sustainedand Controlled Release Drug Delivery Systems, J.R.Robinsoned., Marcel Dekker, Inc., New York, 1978, and R.W.Baker, Controlled Release of Biologically Active Agents, John Wiley﹠Sons, New York, 1987.
Following specific embodiment is the synthetic and test that is used to set forth representative compounds of the present invention, and they are not limited to scope of the present invention.In an embodiment, " m.p. " represents fusing point, and " [α] 25D " is in the time of 25 ℃, shown in specific rotation under the solvent, given concentration, " FAB " is that fast atom bombardment mass spectroscopy(FABMS) and " AAA " are amino acid analysises, is desired value in the observed value unquote wherein.Amino acid analysis carries out according to the scheme of manufacturers's suggestion on Hewlett-Packard AminoQuant Ana-lyzer.One-level amino acid is derived with Phthalyldicarboxaldehyde, and secondary amino acid is derived with Fmoc.Derivative amino is carried out the fluoroscopic examination quantitative analysis.Protected amino acid derive from Applied Biosystems Inc. (Foster City, CA).
The embodiment I adopts solid phase synthesis process, on 4-methyldiphenyl methylamine resin, with the compound 1 (SEQ ID NO:7) about the synthetic 0.5mmol of AppliedBiosystems Model 430A automatic peptide synthesizer.Alpha-amino group is protected with tertiary butyl carbonyl (Boc).The side chain protected group is as follows: to Asp, and Glu, and Ser benzyl (Bzl); To Arg tosyl group (Tos); To His benzyloxymethyl (Bom); To Lys 2-benzyl chloride base (Cl-z).Press the method for Stewart and Young (source as above), use N, N-dicyclohexyl carbodiimide (DCC)/I-hydroxybenzotriazole (HOBt) links to each other these amino acid successively.With each amino acid coupled after, the mixture in N-Methyl pyrrolidone makes the peptide acetylize with diacetyl oxide and diisopropylethylamine., in the presence of methyl-phenoxide, handled 30 minutes and 0 ℃ of processing 60 minutes with anhydrous HF (25mL) at-10 ℃, thereby with the cracking and slough the side chain protected group simultaneously from the resin of synthetic peptide.Vacuum boils off after the HF, and with anhydrous ether wash residual thing, thick peptide extracts with 10% acetate.With 10% acetic acid extraction thing freeze-drying, obtain 900 milligrams of thick products.With the reverse column chromatography of the ODS of middle pressure, adopt 22-45%CH among the 0.1%TFA
3CN gradient purified peptide.Product is gone out 3 parts by wash-out, concentrate and freeze-drying after, obtain 130 milligrams, the white solid of purity>98%.
AVSEHQLLHDKGKSIQDLRRRELLEKLLEKLHTA-NH2 (SEQ ID NO:7) physical data: m.p.150-159 ℃ [α]
25 D-34.88* (c0.16, H
2O) FAB (C
175H
300N
56O
51): [M+H]+4005.5AAA:Asp, 1.9 (2); Glu, 5.6 (6); Ser, 1.6 (2); His, 2.7 (3); Gly, 1.0 (1); Thr, 0.9 (1);
Ala,1.9(2);Arg,2.8(3);Val,1.0(1);Ile,0.9(1);Leu,7.3(8);Lys,4.0(4).
Similarly, preparation compound 2,5-18, and 21-70, and the characteristic of definite these compounds.Be the polypeptide of hydroxyl wherein, replace the PAM resin on demand for synthetic end.
AVSEHQLLHDKGKSIQDLRRRELLEKLLEKLHTA-OH (SEQ ID NO:6) physical data: m.p.154-170 ℃ [α]
25 D-49.35 ° of (c0.46, H
2O) FAB (C
175H
301N
57O
50): [M+H]
+4005.0AAA:Asp, 2.1 (2); Glu, 5.9 (6); Ser, 1.7 (2); His, 2.9 (3); Glyl.1 (1); Thr, 1.0 (1);
Ala,1.9(2);Arg,3.0(3);Val,1.2(1);Ile,1.0(1);Leu,7.8(8);Lys,4.2(4).
AVSEHQLLHDKGKSIQDLRRRELLERLLERLHTA-OH (SEQ ID NO:15) physical data: m.p.147-165 ℃ [α]
25 D49.17 ° (c0.66, H
2O) FAB (C
175H
299N
59O
52): [M+H]
+4061AAA:Asp, 2.1 (2); Gly, 6.1 (6); Ser, 1.8 (2); His, 3.1 (3); Gly, 1.1 (1); Thr, 1.0 (1);
Ala,2.0(2);Arg,5.0(5);Val,1.0(1);Ile,0.9(1);Leu,7.7(8);Lys,1.9(2).
Compound 6
AVSEHQLLHDRGRSIQDLRRRELLERLLERLHTA-OH (SEQ ID NO:16) physical data: m.p.150-170 ℃ [α]
25 D-48.65 ° of (c0.54, H
2O) FAB (C
175H
299N
63O
52): [M+H]
+4118.0AAA:Asp, 2.1 (2); Glu, 6.1 (6); Ser, 1.8 (2); His, 3.2 (3); Gly, 1.2 (1); Thr, 1.0 (1);
Ala,2.0(2);Arg,6.9(7);Val,1.0(1);Ile,1.0(1);Leu,7.8(8).
Compound 7
AVSEHQLLHDRGRSIQDLRRRELLERLLKRLHTA-OH (SEQ ID NO:17) physical data: m.p.177-182 ℃ [α]
25 D-46.17 ° of (c0.14, H
2O) FAB (C
176H
304N
60O
50): [M+H]
+4117AAA:Asp, 2.0 (2); Glu, 4.8 (5); Ser, 1.8 (2); His, 3.2 (3); Gly, 1.1 (1); Thr, 0.9 (1);
Ala,1.9(2);Arg,6.7(7);Val,1.0(1);Ile,1.0(1);Lys,7.7(8);Lys,0.9(1).
Compound 8
AVSEHQLLHDKGKSIQDLRRRELLEKLLRKLHTA-OH (SEQ ID NO:5) physical data: m.p.147-165 ℃ [α]
25 D-49.17 ° of (c0.66, H
2O) FAB (C
176H
305N
59O
49): [M+H]
+4033.0AAA:Asp, 2.0 (2); Glu, 4.8 (5); Ser, 1.8 (2); His, 2.7 (3); Gly, 1.1 (1); Thr, 0.9 (1);
Ala,2.0(2);Arg,3.9(4);Val,1.0(1);Ile,1.0(1);Leu,7.9(8);Lys,4.0(4).
Compound 9
AVSEHQLLHDKGKSIQDLRRRELLEKLLEKLHTAGRR-OHSEQ ID NO:10) physical data: m.p.158-160 ℃ [α]
25 D-44.76 ° of (c0.1, H
2O) FAB (C
189H
326N
64O
55): [M]
+4375.0AAA:Asp, 2.0 (2); Glu, 5.9 (6); Ser, 1.7 (2); His, 2.9 (3); Gly, 2.3 (2); Thr, 1.0 (1);
Ala,1.9(2);Arg,5.0(5);Val,1.2(1);Ile,1.0(1);Leu,7.8(8);Lys,4.3(4).
AVSEAQLLHDLGKSIQDLRRRELLEKLLEKLHAL-OH (SEQ ID NO:14) physical data: m.p.170-175 ℃ [α]
25 D-31.59 ° of (c0.54, H
2O) FAB (C
174H
300N
52O
51): [M+H]
+3936.0AAA:Asp, 2.0 (2); Glu, 6.0 (6); Ser, 1.8 (2); His, 2.0 (2); Gly, 1.2 (1); Ala, 3.0 (3);
Arg,2.8(3);Val,1.1(1);Ile,1.0(1);Leu,9.9(10);Lys,3.0(3).
AVSEHQLLHDKGKSIQDLRRRELLEKLLELLKEL-NH
2(SEQ ID NO:11) physical data: m.p.172-174 ℃ [α]
25 D-43.29 ° of (c0.2, H
2O) FAB (C
179H
311N
55O
52): [M+H]
+4065.8AAA:Asp, 2.2 (2); Glu, 7.7 (7); Ser, 1.7 (2); His, 2.0 (2); Gly, 1.0 (1); Ala, 1.0 (1);
Arg,3.0(3);Val,1.1(1);Ile,1.0(1);Leu,9.3(9);Lys,5.1(5).
Compound 12 AVSEIQFXHNLGKHLSSXERVELLEKLLEKLHNY-NH
2(X=Nle, SEQ ID NO:23) physical data: m.p.178 ℃ [α]
25 D-36.88 ° of (c0.4, H
2O) FAB (C
182H
295N
50O
51): [M+H]
+4001.6AAA:Asp, 2.1 (2); Glu, 6.5 (6); Ser, 2.7 (3); His, 3.1 (3); Gly, 1.1 (1); Ala, 1.0 (1);
Arg,1.0(1);Tyr,0.8(1);Val,2.0(2);Phe,1.0(1);Ile,0.9(1);Leu+Nle,
8.5(7+2);Lys,3.1(3).
Compound 13 AVSEIQFXHNLGKHLSSXRRRELLEKLLEKLHNY-NH
2(X=Nle, SEQ ID NO:24) physical data: m.p.260 ℃ [α]
25 D-37.02 ° of (c0.2, H
2O) FAB (C
184H
304N
56O
49): [M+H]
+4084AAA:Asp, 2.1 (2); Glu, 5.5 (5); Ser, 2.6 (3); His, 3.1 (3); Ala, 1.0 (1); Gly, 1.1 (1);
Arg,3.2(3);Tyr,1.0(1);Val,1.0(1);Phe,1.0(1);Ile,1.0(1);Leu,9.0(9);
Lys,3.0(3).
Compound 14
AVSEHQLLHDKGKSIQDLRRRALAEALAEALHTA-NH
2(SEQ ID NO:20) physical data: m.p.190-225 ℃ [α]
25 D-56.58 ° of (c0.36, H
2O) FAB (C
161H
272N
54O
49): [M+H]
+3747.0AAA:Asp, 2.1 (2); Glu, 4.9 (5); Ser, 1.7 (2); His, 2.6 (3); Gly, 1.1 (1); Thr, 1.0 (1); Ala, 7.6 (7); Arg, 2.8 (3); Val, 1.2 (1); Ile, 1.0 (1); Leu, 6.6 (6); Lys, 1.9 (2).
Compound 15
AVSEHQLLHDKGKSIQDLARRELLEKLLEKLHTA-NH
2(SEQ ID NO:12) physical data: m.p.170-180 ℃ [α]
25 D-48.19 ° of (c0.2, H
2O) FAB (C
172H
293N
53O
51): [M+H]
+3919.0AAA:Asp, 2.1 (2); Glu, 6.1 (6); Ser, 1.7 (2); His, 3.1 (3); Gly, 1.1 (1); Thr, 1.0 (1);
Ala,3.0(3);Arg,2.1(2);Val,1.1(1);Ile,1.0(1);Leu,8.0(8);Lys,4.4(4).
Compound 16
AVSEHQLLHDKGKSIQDLRRAELLEKLLEKLHTA-NH
2(SEQ ID NO:13) physical data: m.p.190-195 ℃ [α]
25 D-50.50 ° of (c0.4, H
2O) FAB (C
172H
293N
53O
51): [M+H]
+3919.0AAA:Asp, 2.1 (2); Glu, 6.0 (6); Ser, 1.8 (2); His, 3.1 (3); Gly, 1.1 (1); Thr, 1.0 (1);
Ala,3.0(3);Arg,2.1(2);Val,1.1(1);Ile,1.0(1);Leu,7.5(8);Lys,4.2(4).
Compound 17
AVSEHQLLHDKGKSIQDLRRRSLLSSLLSSLHTA-NH
2(SEQ ID NO:21) physical data: m.p.195-204 ℃ [α]
25 D-67.11 ° of (c0.3, H
2O) FAB (C
163H
280N
54O
50): [M+H]
+3796.0AAA:Asp, 2.1 (2); Glu, 2.9 (3); Ser, 6.8 (7); His, 3.1 (3); Gly, 1.2 (1); Thr, 1.0 (1);
Ala,2.0(2);Arg,3.0(3);Val,1.0(1);Ile,1.0(1);Leu,8.2(8);Lys,2.0(2).
AVSEHQLLHDKGKSIQDLRRRAFYDKVAEKLHTA-NH
2(SEQ ID NO:22) physical data: m.p.200-207 ℃ [α]
25 D-60.26 ° of (c0.6, H
2O) FAB (C
174H
284N
56O
50): [M+H]
+3960.0AAA:Asp, 2.9 (3), Glu, 3.5 (4); Ser, 1.4 (2); His, 2.6 (3); Gly, 0.9 (1); Thr, 1.0 (1);
Ala,4.0(4);Arg,3.0(3);Tyr,0.9(1);Val,1.9(2);Phe,1.1(1);Ile,0.9(1);
Leu,3.6(4);Lys,4.1(4).
Compound 21
AVSEIQFLHN LGKHLSSLRR RELLEKLLEK LHNY-NH
2(SEQ ID NO:35) physical data: m.p.148-155 ℃ [α]
25 D-45.97 (c0.26, H
2O) FAB (C
184H
304N
56O
49): [M+H]
+4084AAA:Asx, 2.1 (2); Glx, 5.0 (5); Ser, 2.7 (3); His, 3.0 (3); Gly, 1.0 (1); Ala, 0.9 (1);
Arg,3.1(3);Tyr,0.9(1);Val,1.0(1);Phe,0.9(1);Ile,0.9(1);Leu?9.3(9);
Lys,3.2(3).
Compound 22
AVSEIQFLHN?LGKHLSSLRR?RELLEKLLEK?LHNX-NH
2(SEQ?ID?NO:36)
(X=homoserine) physical data: m.p.69.4-128 ℃ [α]
25 D-43.93 (c0.15, H
2O) FAB (C
179H
302N
56O
49): [M+H]
+4022.9AAA:Asx, 2.0 (2); Glx, 4.9 (5); Ser, 2.6 (3); His, 2.8 (3); Gly, 1.0 (1); Ala, 1.0 (1);
Arg,3.0(3);Val,1.0(1);Phe,1.0(1);Ile,0.9(1);Leu,8.8(9);Lys,3.4(3);
Compound 23
AVSEIQFLHN?KGKHLSSLRR?RELLEKLLEK?LHNX-NH
2(SEQ?ID?NO:37)
(X=homoserine) physical data: m.p.87.1-142.1 ℃ [α]
25 D-52.14 (c0.41, H
2O) FAB (C
179H
303N
57O
49): [M+H]
+4038 AAA:Asx, 2.1 (2); Glx, 4.9 (5); Ser, 2.7 (3); His, 2.8 (3); Gly, 1.0 (1);
hSer,1.0(1);Ala,1.0(1);Arg,3.0(3);Val,1.1(1);Phe,0.9(1);
Ile,0.9(1);Leu,7.9(8);Lys,3.7(4).
Compound 24
AVSEHQLLHD KGKSIQDLKL KELLEKLLEK LHTA-NH
2(SEQ ID NO:38) physical data: m.p.175-182 ℃ [α]
25 D-49.99 (c0.47, H
2O) FAB (C
175H
299N
49O
51): [M+H]
+3906.5AAA:Asx, 2.1 (2); Glx, 6.5 (6); Ser, 1.8 (2); His, 3.1 (3); Gly, 1.1 (1); Thr, 1.0 (1);
Ala,2.1(2);Val,1.1(1);Ile,1.0(1);Leu,9.1(9);Lys,6.5(6).
Compound 25
AVSEHQLLHD KGKSIQDLRR RELLERLLER LHTA-NH
2(SEQ ID NO:39) physical data: m.p.136.5-153.5 ℃ [α]
25 D-32.57 (c0.13, H
2O) FAB (C
175H
300N
60O
51): [M+H]
+4060.8AAA:Asx, 2.2 (2); Glx, 6.2 (6); Ser, 1.8 (2); His, 3.2 (3); Gly, 1.1 (1); Thr, 1.0 (1);
Ala,2.1(2);Arg,5.2(5);Val,1.1(1);Ile,1.1(1);Leu,8.4(8);Lys,2.2(2).
Compound 26
AVSEHQLLHD KGKSIQDLRR RELLERLLER LHTAP-OH (SEQ ID NO:40) physical data: m.p.125.8-127.2 ℃ [α]
25 D-54.62 (c0.23, H
2O) FAB (C
180H
306N
60O
53): [M+H]
+4158.0AAA:Asx, 2.1 (2); Glx, 6.2 (6); Ser, 1.8 (2); His, 2.9 (3); Gly, 1.1 (1); Thr, 1.0 (1);
Ala,2.0(2);Arg,5.1(5);Val,1.0(1);Ile,1.0(1);Leu,8.0(8);Lys,2.1(2);
Pro,1.1(1).
Compound 27 AVSEHQLLHD KGKSIQDLRR RELLERLLER LHTAGRR-OH (SEQ ID NO:41) physical data: m.p.106-137.3 ℃ [α]
25 D-39.55 (c0.67, H
2O) FAB (C
189H
326N
68O
55): [M+H]
+4430.5AAA:Asx, 2.1 (2); Glx, 5.9 (6); Ser, 1.6 (2); His, 2.7 (3); Gly, 2.2 (2); Thr, 1.0 (1);
Ala,1.8(2);Arg,7.3(7);Val,0.8(1);Ile,1.0(1);Leu,8.1(8);Lys,2.1(2).
Compound 28 AVSEHQLLHD KGKSIQDLRR RELLERLLER LHTAGRRX-NH
2(SEQ ID NO:42)
(X=homoserine) physical data: m.p.80 ℃ [α]
25 D-48.64 (c0.09, H
2O) FAB (C
193H
334N
70O
56): [M+H]
+4530.0AAA:Asx, 2.2 (2); Glx, 6.1 (6); Ser, 1.7 (2); His, 3.0 (3); Gly, 1.9 (2);
hSer,1.0(1);Thr,1.0(1);Ala,2.1(2);Arg,7.2(7);Val,0.8(1);
Ile,1.0(1);Leu,8.4(8);Lys,2.1(2).
Compound 29
AVSEHQLLHD KGKSIQDLRR RELLEKLLEK LHTY-NH
2(SEQ ID NO:43) physical data: m.p.160-172 ℃ [α]
25 D-49.85 (c0.34, H
2O) FAB (C
181H
304N
56O
52): [M+H]
+4096.9AAA:Asx, 2.0 (2); Glx, 5.6 (6); Ser, 1.7 (2); His, 3.1 (3); Gly, 1.1 (1); Thr, 0.9 (1);
Ala,0.9(1);Arg,3.0(3);Tyr,0.9(1);Val,1.0(1);Ile,1.0(1);Leu,7.7(8);
Lys,4.4(4).
Compound 30
AVSEHQLLHD KGYSIQDLRR RELLEKLLEK LHTA-NH
2(SEQ ID NO:44) physical data: m.p.130-171 ℃ [α]
25 D-40.65 (c0.34, H
2O) FAB (C
178H
297N
55O
52): [M+H]
+4039.4AAA:Asx, 2.0 (2); Glx, 5.5 (6); Ser, 1.8 (2); His, 3.4 (3); Gly, 1.1 (1); Thr, 1.0 (1);
Ala,2.0(2);Arg,2.9(3);Tyr,0.8(1);Val,1.0(1);Ile,0.9(1);Leu,7.9(8);
Lys,3.4(3).
Compound 31
AVSEHQLLHD KG ℃ of SIQDLRR RELLEKLLEK LHTA-NH
2(SEQ ID NO:45) physical data: m.p.140-160 ℃ [α]
25 D-44.48 (c0.25, H
2O) FAB (C
172H
293N
55O
51S
1): [M+H]
+3979AAA:Asx+Cys, 3.0 (2+1); Glx, 5.6 (6); Ser, 1.7 (2); His, 3.0 (3); Gly, 1.0 (1);
Thr,0.9(1);Ala,1.9(2);Arg,2.5(3);Val,1.0(1);Ile,0.9(1);Leu,7.5(8);
Lys,3.3(3).
Compound 32
AVSEHQLLHD?KGXSIQDLRR?RELLEKLLEK?LHTA-NH
2(SEQ?ID?NO:46)
(X=Cys (CH
2ONH (CH
2)
2NH (biotinyl))) physical data: m.p. (not measuring) [α]
25 D(not measuring) FAB (C
186H
316N
59O
54S
2): [M+H]
+4306.6AAA:Asx, 2.2 (2); Glx, 6.1 (6); Ser, 1.8 (2); His, 3.8 (3); Gly, 1.0 (1); Thr, 1.0 (1);
Ala,2.0(2);Arg,3.1(3);Val,1.1(1);Ile,0.9(1);Leu,8.3(3);Lys,3.3(3),
Compound 33
AVSEHQLLHD?KGXSIQDLRR?RELLEKLLEK?LHTA-NH
2(SEQ?ID?NO:47)
(X=Lys (7-dimethylamino-2-oxygen-2H-1| chromene-4-ethanoyl)) physical data: m.p.135-205 ℃ 1] [α]
25 D-26.92 (c 0.104, the 50%HOAc aqueous solution) FAB (C
188H
311N
57O
54): [M+H]
+4233AAA:Asx, 1.9 (2); Glx, 6.3 (6); Ser, 1.7 (2); His, 3.2 (3); Gly, 1.0 (1); Thr, 1.1 (1);
Ala,2.0(2);Arg,3.2(3);Val,1.1(1);Ile,0.9(1);Leu,8.2(8);Lys,4.5(4).
Compound 34
AVSEHQLLHD KGKSIQDLRR RELLEKLLEK LHTAG-OH (SEQ ID NO:48) physical data: m.p.92.1-146.6 ℃ [α]
25 D-40.76 (c0.34, H
2O) FAB (C
177Hc
302N
56O
53): [M+H]
+4062.0AAA:Asx, 2.0 (2); Glx, 5.7 (6); Ser, 1.8 (2); His, 3.0 (3); Gly, 2.2 (2); Thr, 0.9 (1);
Ala,1.9(2);Arg,2.8(3);Val,1.2(1);Ile,0.9(1);Leu,7.5(8);Lys,4.2(4).
Compound 35
AVSXHQLLHZ?KGKSIQZLRR?RXLLXKLLXK?LHA-OH(SEQ?ID?NO:49)
(X=Glu (OCH
3); Z=Asp (OCH
3)) physical data: m.p. (not measuring) [α]
25 D-21.96 (c0.132, H
2O) FAB (C
181H
311N
55O
52): [M+H]
+4089.0AAA:Asx, 2.1 (2); Glx, 6.3 (6); Ser, 1.8 (2); His, 3.3 (3); Gly, 1.1 (1); Thr, 1.0 (1);
Ala,2.0(2);Arg,3.1(3);Val,1.1(1);Ile,0.9(1);Leu,8.0(8);Lys,4.2(4).
Compound 36
AVSXHQLLHZ?KGKSIQZLRR?RXLLXKLLXK?LHA-OCH
3(SEQ?ID?NO:50)
(X=Glu (OCH
3); Z=Asp (OZCH
3)) physical data: m.p. (not measuring) [α]
25 D-46.80 (c0.07, H
2O) FAB (C
182H
313N
55O
52): [M+H]
+4103AAA:Asx, 2.1 (2); Glx, 6.2 (6); Ser, 1.4 (2); His, 3.0 (3); Gly, 1.1 (1); Thr, 1.1 (1);
Ala,1.7(2);Arg,3.2(3);Val,0.6(1);Ile,0.9(1);Leu,8.0(8);Lys,4.1(4).
Compound 37
AVSEHQLLHD?KGKSIQDLRR?RELLEKLLEK?LHTX-OH(SEQ?ID?NO:51)
(X=homoserine) physical data: m.p. (not measuring) [α]
25 D(not measuring) FAB (C
176H
301N
55O
53): [M+H]
+4035.1AAA:Asx, 2.1 (2); Glx, 5.9 (6); Ser, 2.0 (2); His, 3.1 (3); Gly, 0.8 (1);
hSer,0.8(1);Thr,1.0(1);Ala,1.0(1);Arg,3.0(3);Val,1.3(1);
Ile,1.0(1);Leu,8.1(8);Lys,3.8(4).
Compound 38
AVSEHQLLHD KGKSIQDLRR RELLEKLLEK LHTAP-OH (SEQ ID NO:52) physical data: m.p.152.1-186.5 ℃ [α]
25 D-55.91 (c0.33, H
2O) FAB (C
180H
306N
56O
53): [M+H]
+4102.6AAA:Asx, 2.0 (2); Glx, 5.6 (6); Ser, 1.7 (2); His, 2.9 (3); Gly, 1.1 (1); Thr, 0.9 (1);
Ala,1.9(2);Arg,2.9(3);Val,1.2(1);Ile,1.0(1);Leu,7.7(8);Lys,4.3(4).
Compound 39
AVSEHQLLHD KGKSIQDLRR RELLEKLLEK LHTP-OH (SEQ ID NO:53) physical data: m.p.120-148.2 ℃ [α]
25 D-52.78 (c0.47, H
2O) FAB (C
177H
301N
55O
52): [M+H]
+4031.0AAA:Asx, 2.0 (2); Glx, 5.5 (6); Ser, 1.8 (2); His, 2.9 (3); Gly, 1.0 (1); Thr, 1.0 (1);
Ala,0.9(1);Arg,2.9(3);Val,1.2(1);Ile,0.9(1);Leu,7.5(8);Lys,3.6(3);
Pro,0.9(1).
Compound 40
AVSEHQLLHD KGKSIQDLRR RELLEKLLEK LHTP-NH
2(SEQ ID NO:54) physical data: m.p.133.9-155.1 ℃ [α]
25 D-54.22 (c0.37, H
2O) FAB (C
177H
302N
56O
51): [M+H]
+4030.7AAA:Asx, 2.0 (2); Glx, 5.6 (6); Ser, 1.9 (2); His, 2.9 (3); Gly, 1.1 (1); Thr, 0.9 (1);
Ala,0.9(1);Arg,2.8(3);Val,1.2(1);Ile,1.1(1);Leu,7.8(8);Lys,4.2(4);
Pro,0.9(1).
Compound 41
AVSEHQLLHD KGKSIQDLRR RELLEKLLEK LHP-NH
2(SEQ ID NO:55) physical data: m.p.142.8-166.1 ℃ [α]
25 D-53.80 (c0.38, H
2O) FAB (C
173H
295N
55O
49): [M+H]
+3929AAA:Asx, 2.0 (2); Glx, 5.7 (6); Ser, 1.8 (2); His, 3.0 (3); Gly, 1.1 (1); Ala, 0.9 (1);
Arg,2.8(3);Val,1.2(1);Ile,0.9(1);Leu,7.4(8);Lys,4.4(4);Pro,0.9(1).
Compound 42
AVSEHQLLHD KGKSIQDLRR RELLEKLLEK LP-NH
2(SEQ ID NO:56) physical data: m.p.161.0-177.0 ℃ [α]
25 D-61.97 (c0.19, H
2O) FAB (C
167H
288N
52O
48): [M+H]
+3792.0AAA:Asx, 2.2 (2); Glx, 5.9 (6); Ser, 1.9 (2); His, 2.1 (2); Gly, 1.1 (1); Ala, 1.0 (1);
Arg,3.0(3);Val,1.1(1);Ile,1.0(1);Leu,7.9(8);Lys,4.3(4);Pro,0.9(1).
Compound 43 AVSEHQLLHD KGKSIQDLRR RELLEKLLEK LHTRSAW-OH (SEQ ID NO:57) physical data: m.p.181-202 ℃ [α]
25 D-45.14 (c0.19, H
2O) FAB (C
195H
326N
62O
56): [M+H]
+4435.2AAA:Asx, 2.0 (2); Glx, 5.8 (6); Ser, 2.8 (3); His, 2.8 (3); Gly, 1.1 (1); Thr, 0.9 (1);
Ala,1.9(2);Arg,3.7(4);Ile,0.9(1);Leu,7.5(8);Lys,4.3(4);Trp,0.9(1).
Compound 44
AVSEHQLLHD RGRSIQDLRR RELLERLLER LHTAGRRTRSAW-OH (SEQID NO:58) physical data: m.p.130-132.2 ℃ [α]
25 D-46.66 (c0.195, H
2O) FAB (C
216H
365N
81O
62): [M+H]
+5088.8AAA:Asx, 2.2 (2); Glx, 6.0 (6); Ser, 2.7 (3); His, 3.0 (3); Gly, 2.2 (2); Thr, 2.1
(2);Ala,3.0(3);Arg,10.5(10);Val,0.9(1);Ile,1.0(1);Leu,8.2(8);Trp,
1.0(1).
Compound 45
AVSEHQLLHD RGRSIQDLRR RELLERLLER LHTAGRRTRSAW-NH
2(SEQ ID NO:59) physical data: m.p.158-174 ℃ [α]
25 D-43.57 (c0.53, H
2O) FAB (C
216H
365N
82O
61): [M+H]
+5087.4AAA:Asx, 1.9 (2); Glx, 5.6 (6); Ser, 2.6 (3); His, 3.3 (3); Gly, 2.1 (2); Thr, 2.0 (2);
Ala,2.9(3);Arg,10.1(10);Val,0.9(1);Ile,1.0(1);Leu,8.3(8);Trp1.1(1).
Compound 46
AVSEHQLLHD?RGXSIQDLRR?RELLERLLER?LHTAGRRTRSAW-OH(SEQ?ID?NO:60)
(X=Lys (dihydro cinnamon acyl group)) physical data: m.p.165.4-175.2 ℃ [α]
25 D-40.43 (c0.20, H
2O) FAB (C
225H
374N
80O
62): [M+H]
+5191AAA:Asx, 2.1 (2), Glx, 6.3 (6); Ser, 2.8 (3); His, 3.2 (3); Gly, 2.1 (2), Thr, 2.0
(2);Ala,3.2(3);Arg,9.9(9);Val,1.0(1),Ile,0.9(1);Leu,8.6(8);Lys,1.1
(1);Trp,1.1(1).
Compound 47
AVSEIQFXHN?LGKHLSSXTR?SAWLRKKLQD?VHNY-NH
2(SEQ?ID?NO:61)
(X=nor-leucine) physical data: m.p.140-160 ℃ [α]
25 D-56.88 (c0.16, H
2O) FAB (C
180H
287N
56O
58); [M+H]
+3989.8AAA:Asx, 3.0 (3); Glx, 2.9 (3); Ser, 3.7 (4); His, 2.8 (3); Gly, 1.1 (1); Thr, 0.9 (1);
Ala,1.9(2);Arg,2.0(2);Tyr,1.0(1);Val,1.7(2);Phe,0.9(1);Ile,0.9(1);
Leu+Nle5.8(2+4);Lys,3.4(3);Trp,1.1(1).
Compound 48
AVSEHQLLHD KGKSJQDLRR RELLSEKLLEK LHTMA-NH
2(SEQ ID NO:62) physical data: m.p.140-210 ℃ [α]
25 D-47.75 (c0.178, H
2O) FAB (C
180H
309N
57O
52S
1): [M+H]
+4135.0AAA:Asx, 2.3 (2); Glx, 6.6 (6); Ser, 1.4 (2); His, 3.2 (3); Gly, 1.1 (1); Thr, 1.0 (1);
Ala,2.0(2);Arg,3.1(3);Val,0.9(1);Met,1.1(1);Ile,1.0(1);Leu,8.8(8);
Lys,4.4(4).
Compound 49
AVSEHQLLHD?KGKSIQDLRR?RELLEKLLEK?LHTX(SEQ?ID?NO:63)
(X=1,4-diamino butyrolactam) physical data: m.p.161-181 ℃ [α]
25 D-48.38 (c0.25, H
2O) FAB (C
176H
300N
56O
51): [M+H]
+4016.8AAA:Asx, 2.1 (2); Glx, 6.3 (6); Ser, 1.7 (2); His, 3.3 (3); Gly, 1.1 (1); Thr, 1.0 (1);
Ala,2.1(2);Arg,2.9(3);Val,0.9(1);Ile,0.9(1);Leu,8.0(8);Lys,3.8(4)
Compound 50
AVSEHQLLHD KGKSIQDLRR RFFLEKLLEK LHTA-NH
2(SEQ ID NO:64) physical data: m.p.136.5-156.8 ℃ [α]
25 D-49.89 (c0.24, H
2O) FAB (C
182H
300N
56O
49): [M+H]
+4056.0AAA:Asx, 2.2 (2); Glx, 5.0 (5); Ser, 1.9 (2); His, 3.3 (3); Gly, 1.0 (1); Thr, 1.0 (1);
Ala,2.1(2);Arg,3.1(3);Val,1.0(1);Phe,2.0(2);Ile,0.9(1);Leu,7.2(7);
Lys,3.5(4).
Compound 51
AVSEHQLLHD KGKSIQDLRR RELLHKLLEK LHTA-NH
2(SEQ ID NO:65) physical data: m.p.80.7-141.0 ℃ [α]
25 D-55.38 (c0.23, H
2O) FAB (C
176H
300N
58O
49): [M+H]
+4012.8AAA:Asx, 2.2 (2); Glx, 4.9 (5); Ser, 1.8 (2); His, 4.3 (4); Gly, 1.1 (1); Thr, 1.0 (1):
Ala,2.0(2);Arg,3.1(3);Val,1.1(1);Ile,1.0(1);Leu,8.1(8);Lys,3.9(4).
Compound 52
AVSEHQLLHD KGKSIQDLRR RELLEHLLEK LHTA-NH
2(SEQ ID NO:66) physical data: m.p.134.3-157.9 ℃ [α]
25 D-50.72 (c0.45, H
2O) FAB (C
175H
295N
57O
51): [M+H]
+4012.8AAA:Asx, 2.1 (2); Glx, 5.9 (6); Ser, 1.8 (2); His, 4.2 (4); Gly, 1.1 (1); Thr, 1.0 (1);
Ala,2.0(2);Arg,3.0(3);Val,1.1(1);Ile,0.9(1);Leu,8.1(8);Lys,3.1(3).
Compound 53
AVSEHQLLHD KGKSIQDLRR RELLEKLIAK LHTA-NH
2(SEQ ID NO:67) physical data: m.p.142.7-159.8 ℃ [α]
25 D-54.01 (c0.21, H
2O) FAB (C
173H
298N
56O
49): [M+H]
+3946.0AAA:Asx, 2.2 (2); Glx, 4.9 (5); Ser, 1.8 (2); His, 3.1 (3); Gly, 1.1 (1); Thr, 1.0 (1);
Ala,3.1(3);Arg,3.1(3):Val,1.0(1);Ile,1.9(2);Leu,7.0(7);Lys,4.3(4).
Compound 54
AVSEHQLLHD KGKSIQDLRR RELLEKLLEE 1HTA-NH
2(SEQ ID NO:68) physical data: m.p.138-185 ℃ [α]
25 D-50.17 (c0.14, H
2O) FAB (C
174H
295N
55O
53): [M+H]
+4005AAA:Asx, 2.2 (2); Glx, 7.1 (7); Ser, 1.7 (2); His, 2.8 (3); Gly, 1.0 (1); Thr, 1.0 (1);
Ala,2.1(2);Arg,3.1(3);Val,1.1(1);Ile,1.7(2);Leu,7.1(7);Lys,2.7(3).
Compound 55AVSEHQLLHD KGKSIQDLRR RELLEKLLEK LHTX-NHCH
2CH
3(SEQ ID NO:69)
(X=homoserine) physical data: m.p. (not measuring) [α]
25 D(not measuring) FAB (C
178H
306N
56O
52): [M+H]
+4063.0AAA:Asx, 2.1 (2); Glx, 5.8 (6); Ser, 1.7 (2); His, 3.1 (3); Gly, 0.9 (1); Thr, 1.0 (1);
Ala,0.9(1);Arg,3.0(3);Val,1.1(1);Ile,1.0(1);Leu,8.4(8);Lys,3.7(4);
hSer,0.9(1).
Compound 56
AVSEHQLLHD?KGKSIQDLRR?RELLEKLLEK?LHTX-NHCH
2CH
2C
6H
5(SEQID?NO:70)
(X=homoserine) physical data: m.p. (not measuring) [α]
25 D(not measuring) FAB (C
184H
310N
56O
52): [M+H]
+4138.8AAA:Asx, 2.0 (2); Glx, 5.9 (6); Ser, 1.7 (2); His, 2.9 (3); Gly, 0.9 (1); Thr, 1.0 (1);
Ala,0.9(1);Arg,3.0(3);Val,1.0(1);Ile,0.9(1);Leu,8.0(8);Lys,4.1(4);
hSer,0.9(1).
Compound 57
Physical data: m.p.142.5-163.5 ℃ [α]
25 D-34.31 (c0.17, H
2O) FAB (C
175H
298N
56O
50): [M+H]
+3986.4AAA:Asx, 1.9 (2); Glx, 5.9 (6); Ser.1.8 (2); His, 3.2 (3); Gly, 1.1 (1); Ala, 2.0 (2);
Arg,3.0(3);Thr,1.0(1):Val,1.1(1);1le,0.9(1);Leu,8.0(8);Lys,4.0(4).
Compound 58AVSEHQLLHD KGKSIQDLRR RELLEKLLEK LHTRSAW-NH
2(SEQ ID NO:72) physical data: m.p.158-163 ℃ [α]
25D-46.06 (c0.17, H
2O) FAB (C
195H
327N
63O
55): [M+H]
+4434.8AAA:Asx, 2.0 (2); Glx, 5.5 (6); Ser, 2.7 (3); His, 3.1 (3); Gly, 1.0 (1); Ala, 1.8 (2);
Arg,4.0(4);Thr,0.9(1);Val,0.9(1);Ile,0.9(1);Leu,7.5(8);Lys,3.9
(4);Trp,1.0(1).
Compound 59AVSEHQLLHD KGKSIQDLRR RELLEKLLEK LHTRSAX-OH (SEQ ID NO:73)
(X=Nal (2)=3-(2-naphthyl)-L-L-Ala) physical data: m.p.156-162 ℃ [α]
25 D-44.44 (c0.189, H
2O) FAB (C
197H
328N
62O
55): [M+H]
+4445.6AAA:Asx, 2.1 (2); Glx, 5.5 (6); Ser, 2.8 (3); His, 2.9 (3); Gly, 1.0 (1); Ala, 2.0 (2);
Arg,4.0(4);Thr,0.9(1);Val,1.0(1);Ile,0.9(1);Leu.7.5(8);Lys,4.2(4);
Nal,1.1(1).
Compound 60AVSEHQLLHD KGKSIQDLRR RELLEKLLEK LHTASAW-OH (SEQ ID NO:74) physical data: m.p.159-164 ℃ [α]
25 D-50.94 (c0.29, H
2O) FAB (C
192H
320N
60O
55): [M+H]
+4349.0AAA:Asx, 2.0 (2); Glx, 5.6 (6); Ser, 2.7 (3); His, 3.2 (3); Gly, 1.0 (1); Ala, 3.1 (3);
Arg,2.8(3);Thr,1.0(1);Val,1.1(1);Ile,0.9(1);Leu,7.6(8);Lys,4.0(4);
Trp,1.0(1).
Compound 61AVSEHQLLHD KGKSIQDLRR RELLEKLLEK LHTAEIRA-OH (SEQ ID NO:75) physical data: m.p.155-210 ℃ [α]
25 D-46.15 (c0.12, H
2O) FAB (C
195H
334N
62O
58): [M+H]
+4475.8AAA:Asx, 2.2 (2); Glx, 6.9 (7); Ser, 1.7 (2); His, 3.2 (3); Gly, 1.1 (1); Ala, 3.1 (3);
Arg,4.0(4);Thr,0.9(1);Val,1.1(1);Ile,1.9(2);Leu,8.1(8);Lys,4.1(4).
Compound 62
AVSEHQLLHD KGKSIQDLRR RELLEKLLEK LHTAEIR-OH (SEQ ID NO:76) physical data: m.p.186-218 ℃ [α]
25 D-52.73 (c0.265, H
2O) FAB (C
192H
329N
61O
57): [M+H]
+4404.4AAA:Asx, 2.0 (2); Glx, 6.6 (7); Ser, 1.9 (2); His, 3.4 (3); Gly, 1.1 (1); Ala, 2.0 (2);
Arg,3.8(4);Thr,1.0(1);Val,1.1(1);Ile,1.7(2);Leu,7.9(8);Lys,4.0(4).
Compound 63AVSEHQLLHD KGKSIQDLRR RELLEKLLEK LHTAEI-OH (SEQ ID NO:77) physical data: m.p.169-205 ℃ [α]
25 D-50.78 (c0.51, H
2O) FAB (C
186H
317N
57O
56): [M+H]
+4248.0AAA:Asx, 2.2 (2); Glx, 6.8 (7); Ser, 1.8 (2); His, 3.3 (3): Gly, 1.0 (1); Ala, 2.0 (2);
Arg,3.0(3);Thr,1.0(1);Val,1.0(1);Ile,1.8(2);Leu,7.8(8);Lys,3.6(4).
Compound 64
AVSEHQLLHD KGKSIQDLRR RELLEKLLEK LHTAE-OH (SEQ ID NO:78) physical data: m.p.199-205 ℃ [α]
25 D-52.47 (c0.41, H
2O) FAB (C
180H
306N
56O
55): [M+H]
+4135.0AAA:Asx, 2.0 (2); Glx, 6.6 (7); Ser, 1.9 (2); His, 3.3 (3); Gly, 1.1 (1); Ala, 2.0 (2);
Arg,2.9(3);Thr,1.0(1);Val,1.1(1);Ile,1.0(1);Leu,8.2(8);Lys,3.8(4).
Compound 65
AVSEIQFX
1HN?KGKHLSSX
1ER?VEWLRKKLQD?VHNX
2(SEQ?ID?NO:79)
(X
1=L-nor-leucine; X
2=Kos oxygen acid lactone) physical data: m.p.166-176 ℃ [α]
25 D-52.22 (c0.25, H
2O) FAB (C
180H
288N
54O
50): [M+H]
+4008.6AAA:Asx, 3.1 (3); Glx, 4.8 (5); Ser, 2.9 (3); His, 2.9 (3); Gly, 1.1 (1); Ala, 1.1 (1);
Arg,2.0(2);Val,2.7(3);Phe,1.0(1);Ile,1.0(1);Leu+Nle?5.9(4+2);
Lys,2.8(3).
Compound 66
SEHQLLHD KGKSIQDLRR RELLEKLLEK LHTA-NH
2(SEQ ID NO:80) physical data: m.p.134.2 ℃ [α]
25 D-48.12 (c0.36, H
2O) FAB (C
167H
286N
54O
49): [M+H]
+3834.4AAA; Asx, 2.0 (2); Glx, 5.7 (6); Ser, 1.7 (2); His, 2.9 (3); Gly, 1.0 (1); Thr, 0.9 (1);
Ala,1.0(1);Arg,2.8(3);Ile,0.9(1);Leu,7.4(8);Lys,4.3(4).
Compound 67
LLHD KGKSIQDLRR RELLEKLLEK LHTA-NH
2(SEQ ID NO:81) physical data: m.p.128.5-184.5 ℃ [α]
25 D-6.53 (c0.69, MeOH) FAB (C
148H
259N
47O
41): [M+H]
+3353AAA:Asx, 2.0 (2); Glx, 4.1 (4); Ser, 0.9 (1); His, 2.1 (2); Gly, 1.0 (1); Thr, 0.9 (1);
Ala,1.0(1);Arg,3.0(3);Ile,1.0(1);Leu,8.1(8);Lys,4.2(4).
Compound 68
LHD KGKSIQDLRR RELLEKLLEK LHTA-NH
2(SEQ ID NO:82) physical data: m.p.165-210 ℃ [α]
25 D-36.05 (c0.12, H
2O) FAB (C
142H
248N
46O
40): [M+H]
+3239.0AAA:Asx, 2.0 (2); Glx, 3.9 (4); Ser, 0.9 (1); His, 1.9 (2); Gly, 1.0 (1); Thr, 1.0 (1);
Ala,1.0(1);Arg,2.9(3);Ile,0.9(1);Leu,6.8(7);Lys,4.2(4).
Compound 69 SEHQLLHD RGRSIQDLRR RELLERLLER LHAGRRTRSAW-OH (SEQ ID NO:83) physical data: m.p.150-210 ℃ [α]
25 D-18.0 (c0.64, H
2O) FAB (C
208H
351N
79O
60): [M+H]
+4918.6AAA:Asx, 2.2 (2); Glx, 6.2 (6); Ser, 2.8 (3); His, 3.1 (3); Gly, 2.2 (2); Thr, 2.2
(2);Ala,2.2(2);Arg,10.4(10);Ile,1.0(1);Leu,8.0(8);Trp,1.1(1).
Compound 70
LLHDRGRSIQDLRR RELLERLLER LHAGRRT RSAW-OH (SEQ ID NO:84) physical data: m.p.150-210 ℃ [α]
25 D-41.70 (c0.36, H
2O) FAB (C
189H
324N
72O
52): [M+H]
+4437.14AAA:Asx, 2.1 (2); Glx, 4.1 (4); Ser, 1.9 (2); His, 2.0 (2); Gly, 2.1 (2); Thr, 2.0 (2);
Ala,2.1(2);Arg,9.7(10);Ile,0.9(1);Leu,7.4(8).
The embodiment II
Step preparation and purifying [Met according to the embodiment I
34, Ala
35] compound 1, AVSEHQLLHDKGKSIQDLRRRELLEK-LLEKLHTMA-NH
2, (SEQ ID NO:25).And with the following method this polypeptide is transformed into homoserine lactone.The peptide (160 milligrams) of purifying is dissolved in 44% formic acid (4 milliliters).With this solution in 0 ℃ be pre-mixed, cyanogen bromide (700 milligrams) and phenol (1.6 milligrams) merges at the solution of 44% formic acid (4 milliliters).Solution stirred 2 hours at 0 ℃, at room temperature stirred then 2 hours.The formation of product HPLC (Vydac
_C-18,300 dusts, 4.6 * 250mm, flow velocity 1.2mL/min, gradient is the 25-45% acetonitrile among the 0.1%TFA, 10 minutes) monitoring.Be reflected in 4 hours and finish.Half sample is concentrated and with preparation property RP-HPLC (Vydac
_C-18, gradient is the 25-45% acetonitrile among the 0.1%TFA).Collect homoserine lactone peptide moiety and freeze-drying, obtain the white solid of 28 milligrams of purity>95%, promptly compound 4.
Compound 4
AVSEHQLLHDKGKSIQDLRRRELLEK LLEKLHTX (X=hSerlac, SEQ ID NO:9) physical data: m.p.138-142 ℃ [α]
25 D-50.66 ° of (c0.1, H
2O) FAB (C
176H
299N
55O
52): [M+H]
+4017.61AAA:Asp, 2.1 (2); Glu, 6.1 (6); Ser, 1.8 (2); His, 3.0 (3);
Thr,1.1(1);Ala,1.1(1);Arg,2.7(3);Val,1.0(1);Ile,
1.0(1);Leu,8.2(8);Lys,3.8(4);Gly1.09(1);hSer,
1.09(1).
The embodiment III
In order to prepare the homoserine acid amides, concentrate thick homoserine lactone (hSerlac) analog compounds 4, use 25 milliliters of saturated NH then
3Methanol solution handle.Solution stirred 2 hours at 0 ℃, at room temperature stirred then 16 hours.Reaction HPLC (Vydac
_C-18,300 dusts, 4.6 * 250mm, flow velocity 1.2mL/min, gradient is the 20-45% acetonitrile among the 0.1%TFA) monitoring, and in 18 hours, finish.Solution concentration is also used preparation property RP-HPLC (Vydac
_C-18, gradient is the 20-45% acetonitrile among the 0.1%TFA) purifying.Collect homoserine amidated peptide part and freeze-drying, obtain the white solid of 30 milligrams of purity>98%, promptly compound 3.
Compound 3AVSEHQLLHDKGKSIQDLRRRELLEKLLEKLHTX-NH
2(X=hSer, SEQ ID NO:8) physical data: m.p.138-142 ℃ [α]
25 D-45.97 ° of (c0.25, H
2O) FAB (C
176H
302N
56O
52): [M+H]
+4033.9AAA:Asp, 2.1 (2); Glu, 6.1 (6); Ser, 1.6 (2); His, 2.8 (3);
Gly,0.97(1);hSer,0.97(1);Thi,1.0(1);Ala,1.0(1);
Arg,2.9(3);Val,1.0(1);Ile,1.0(1);Leu,7.6(8);Lys,
3.9(4).
The embodiment IV
According to the method for embodiment I, protected peptide-resin B ocAVS (Bzl) E (OBz) H (Bom) QLLHD (OBzl) R (Ts) GR (Ts) S (Bzl) IQD (OBz)-LR (Ts) R (Ts) E (OBz) LLE (OBzl) R (Ts) LLK (Fmoc) R (Ts) LH (Bom) T (Bzl) A-O-PAM about preparation 0.35mmol.All N
aGroup is protected with tert-butoxycarbonyl (Boc); The side chain protected group marks.After end of synthesis, at room temperature handled peptide resin 30 minutes with the dimethyl formamide (DMF) of 50 milliliter of 20% piperidines, thereby remove fluorenyl methoxy carbonyl (Fmoc) blocking group on the Methionin.Use DMF subsequently successively, MeOH, and CH
2Cl
2Washing resin, and dry, obtain the peptide that 1.6 gram parts are protected.In 20 milliliters of DMF, in the presence of 0.16g (0.3mmol) phosphofluoric acid benzotriazole base-three (pyrrolidyl) microcosmic salt and 0.067g (0.525mmol) diisopropylethylamine (DIEA), with 0.44 gram (0.3mmol) methoxyl group two (vinyloxy group) acetate [PEG (2) CH
2COOH] make the peptide of 0.8g (0.175mmol) part protection carry out acetylization reaction 5 hours at the Methionin place.After 5 hours, filter resin, use DMF, MeOH and CH then successively
2Cl
2Washing.Repeat acetylize step twice, until on resin, obtaining negative triketohydrindene hydrate result.With the cracking from the resin of final peptide, and as the embodiment I, remove the side chain protected group and carry out purifying.Obtain 100 milligrams of compounds 19.
H
2O)FAB(C
183H
316N
64O
54):[M+H]
+4276.2AAA:Asp,2.1(2);Glu,5.0(5);Ser,1.6(2);His,2.9(3);Gly,0.9(1);Thr,1.9
(2);Arg,7.1(7);Val,1.1(1);Ile,1.0(1);Leu,8.0(8);Lys,0.9(1).
The embodiment V
Synthesize like that, cut and purified peptide by the embodiment IV, except using poly-(vinyloxy group) acetate [PEG (5000) CH of 2-methoxyl group
2CO
2H] as acetylizing agent.Peptide with the protection of 0.8g (0.175mmol) part obtains 300 milligrams of pure compounds 20.
Compound 20
Physical data: m.p.105 ℃ [α]
25 D-22.95 ° of (c0.1l, the 50%HOAc aqueous solution) AAA:Asp, 2.0 (2); Glu, 4.8 (5); Ser, 1.6 (2); His, 2.6 (3); Gly, 1.1 (1); Thr, 1.1
(1);Arg,7.3(7);Val,0.8(1);Ile,0.9(1);Leu,8.3(8);Lys,1.1(1);Ala,
1.8(2).
The embodiment VI
Synthetic hPTHrp (1-34) analogue gene
The synthetic gene of design coding hPTHrp (1-34) analog compounds 4 (SEQ ID NO:9), it has as shown in Figure 1 nucleotide sequence and restriction enzyme site.Essential oligonucleotide dna synthesizer (Milligen/Biosearch), and adopt Sinha, etal., Nucleic Acid Research 12, phosphoramidate (phosphoramidite) the method preparation of 4539-4557 (1984).After going protection, thick oligonucleotide on preparation property 15% polyacrylamide gel by gel electrophoresis purifying.Position with the definite oligonucleotide of UV irradiation cuts out from gel with it then, desalination on Waters c18 Sep-pak_ post, then freeze-drying.
Amplified reaction by polymerase chain reaction is to carry out on Perkin-Elmer Cetus thermal cycler, condition is: 94 ℃ 1 minute, 50 ℃ of 2 minutes and 72 ℃ 3 minutes, " GeneAmp " DNA cloning test kit (Perkin-Elmer Cetus) that comprises the Taq polysaccharase is wherein used in totally 25 circulations.
The oligonucleotide of two kinds of overlappings of preparation, the PTH4 promptly PTH3 of 88 polymers (2 microgram) and antisense, 90 polymers (2 microgram) are as the template DNA sequence of hPTHrp (1-34) analogue gene.PTH3,(SEQ?ID?NO:31):CCTCTAGATC?TCCGCGGCGC?TAGC?ATG?GCT?GTT?TCT?GAA?CAT?CAG?45
Met?Ala?Val?Ser?Glu?His?Gln
1 5CTG?CTT?CAT?GAC?AAA?GGT?AAA?TCG?ATT?CAA?GAT?CTG?AGA?CGT?C
88Leu?Leu?His?Asp?Lys?Gly?Lys?Ser?Ile?Gln?Asp?Leu?Arg?Arg
10 15 20PTH4(SEQ?ID?NO:32):CCTCGAAGCT TATGCATCAT TATCTAGA?CAT?AGT?ATG?CAG?CTT?TTC?46
Met?Thr?His?Leu?Lys?Glu
30AAG?CAG?TTT?CTC?CAG?CAG?CTC?GCG?ACG?TCT?CAG?ATC?TTG?AAT?88Leu?Leu?Lys?Glu?Leu?Leu?Glu?Arg?Arg?Arg?Leu?Asp?Gln?Ile
25 20 15CG 90, adopt both sides primer PTHPCRl:CCTCTAGATC TCCGCGGCGC TAG (SEQ ID NO:33) and PTHPCR2:CCTCGAAGCT TATGCATCAT TATC (SEQ IDNO:34), by the whole gene of pcr amplification.The amplification DNA on the 4%NuSieve_ sepharose by the gel electrophoresis purifying.From gel, cut the band of hPTHrp (1-34) analogue gene that contains about 150 bases of synthetic, use Elu-Quik
_(Schleicher﹠Schuell, Keene NH) isolate about 200ng DNA to glass gel DNA extraction process.
The embodiment VII
The molecular cloning of hPTHrp (1-34) 1 analogue gene
For hPTHrp (1-34) analogue gene of subclone embodiment VI, separate the DNA of 200ng amplification, carry out enzyme with restriction enzyme HinD III and Sac II then and cut.As shown in Figure 2, DNA is connected in TrpLE 18 Prot (Ile3, Pro5) plasmid cut with HinD III and Sac II enzyme of 2 micrograms.
The embodiment VIII makes up Trp LE 18 carriers that contain multiple copied hPTHrp (1-34) analogue gene
Near the beginning of hPTHrp (1-34) analogue gene sequence and end, have unique N he I and Xba I restriction site.The site that can use these two the different sequences of identification but produce identical strand sticky end is at Trp LE 18 vector construction multiple copied hPTHrp (1-34) genes.
The scheme of in Fig. 3, having summarized multiple hPTHrp (1-34) sequence that makes up the tandem arrangement.In each reaction, digest Trp LE 18 hPTHrp (1-34) 1 plasmid that 5 micrograms contain single copy gene with Bam H I+Nhe I and Xba I+Bam H I.From each digest, isolate the fragment that about 300ng contains hPTHrp (1-34) analogue gene.Mix two kinds of fragments and connection, thereby form Trp LE 18 hPTHrp (1-34) 2 plasmids.With these plasmid activity of conversion intestinal bacteria HB 101 cells.Utilize the size of PCR product on 1% sepharose that transforms to determine to exist hPTHrp (1-34) the gene insert of two copies.Confirm to contain Tr-pLE 18 hPTHrp (1-34) 2 of two copy genes then by dna sequencing.Nhe I and Xba I site are eliminated in the correct fusion meeting of two hPTHrp (1-34) gene in the joint.This makes Xba I and Nhe I be still unique in the gene both sides that tandem is arranged.
By repeating this program, make up final plasmid Trp LE 18 hPTHrp (1-34) 4 that contain 4 copy hPTHrp (1-34) genes, as shown in Figure 4.Find that by dna sequence analysis Trp LE 18 hPTHrp (1-34) 4 sequences are correct.
The embodiment IX
Expression and the purifying of Trp LE 18 hPTHrp (1-34) 4
Induce Trp LE 18 hPTHrp (1-34) 4
50 milliliters of LB substratum starting culture (J.H.Miller that will contain 50 mcg/ml penbritins and 100 mcg/ml tryptophanes, Experiments in Molecu-lar Genetics, " p.431 (1972); be incorporated herein by reference) inoculate with the Bacillus coli cells that contains Trp LE 18hPTHrp (1-34) 4 plasmids; acutely shake grow overnight at 37 ℃ then, to A
550Be about 6.2 liters of LB substratum that are used to produce are preheated to 37 ℃, inoculate the A that obtains then with 20 milliliters of starting cultures
550Be about 0.06.Culture grows to A under acutely shaking then
550Be about 0.6-0.8, add 2 milliliters of solution that contain 10mg/mL indole acrylic acid (IAA).Continuation is grown 16 hours until whole A under the good condition of ventilation
550Be about 6 (typically, being 4-10).By centrifugal concentrating cells, and then be suspended in 500mL 50mM Tris-HCl, pH7.5 is in the 0.1mM edta buffer liquid (Tris damping fluid).
Suspension Heat Systems-Ultrasonics, and the 220F type ultrasonoscope of Inc. (be equipped with 3/4 " loud speaker), carry out ultrasonication under (for fear of overheated) at full capacity 50%.
In order to determine the inductive degree, analyze whole cell with SDS-PAGE.Observe from TrpLE 18 hPTHrp (1-34) 4 constructions derive and gene product for estimating the main band of about 17,000 Dalton molecular weights.This band is corresponding to about 10% total cellular protein.
Divide isolated fusion protein
Eccentric cell I lysate is 15 minutes under about 3600 * g, makes Trp LE 18hPTHrp (1-34) 4 fusion roteins deposition; Abandoning supernatant.Settling is suspended in 100 milliliters of Tris damping fluids again (typically is 40-80A
550/ mL)
The embodiment X
The purifying of the processing of fusion rotein and homoserine lactone hPTHrp (1-34) peptide
The methionine(Met) that will be positioned at hPTHrp (1-34) polymer fusion rotein one side with CNBr downcuts, and discharges required homoserine lactone hPTHrp (1-34) polypeptide, carries out purifying by following method then.Handle fusion rotein with CNBr
Washed TrpLE 18 hPTHrp (1-34) 4 fusion rotein settlings are suspended in (about 20mg/mL total protein in 60mL 70% formic acid again by stirring lightly; Typically will be from 1000 A
500The raw material of unit cell is dissolved in 3 milliliters).Add several octanols, use N
2Purge solution 20 minutes adds 5.5g CNBr then.Then, in 25 ℃ of reactions 6 hours, with isopyknic 50: 50 MeOH: H
2O and sample mix are removed by rotary evaporation subsequently.Repeat this process 2-4 time, formic acid and CNBr are removed basically.Evaporate sample then to dry, be dissolved in again in 200 ml waters, freeze-drying stores.The purifying of homoserine lactone hPTHrp (1-34)
With CNBr cracked supernatant liquor at the 50mM KH that changes to some extent
2PO
4Dialysis is 24 hours among the pH6.5.In dialysis, pH maintains 6.5.After the dialysis, the high speed centrifugation disgorging.Supernatant liquor is by Gelman0.45 μ filtration unit (Acrodisc 4184) clarificationization.Cation-exchange chromatography
Initial purifying is by (cation-exchange chromatography on 21.5 * 150mm) is finished at Bio-Gel TSK-SP-5PW HPLC post.Corresponding to flow velocity is that the chromatographic condition of 8mL/min and about 12 milligrams of high purity homoserine lactone hPTHrp (1-34) peptide output is as follows:
1. use 50mM KH
2PO
4, pH 6.5 balance columns
2. adorn the clarifying supernatant liquor of 10mL (about 1.5 liters of nutrient solutions or 2.4g inclusion body).
3. with the 50mM KH that contains 50mM NaCl
2PO
4, the pH6.5 washing column is until baseline stability
4. with the 50mM KH that contains 90mM NaCl
2PO
4, pH6.5 wash-out post.Collected cut about 45 minutes.
5. analyze homoserine lactone hPTHrp (1-34) content in the 90mM NaCl cut with C18 HPLC, collect storage then.The reverse hplc chromatogram
(Perseptive Biosystems, Cambridge MA) carry out last purification step with anti-phase Poros R/H 4.6 * 100 mm posts.This chromatographic condition is as follows: mobile phase A: 0.1% trifluoroacetic acid (TFA)/water
B:0.1% trifluoroacetic acid (TFA)/CH
3CN
Time flow velocity %B
0min 4ml/min 15
5.0min 4ml/min 40
5.2min 4ml/min 100
6.8min 4ml/min 100
7.0min 4ml/min 15
Homoserine lactone hPTHrp (1-34), the retention time of compound 4 is about 2.943 minutes.The peptide of purifying is about 98% with mass spectrometric determination purity.
The embodiment XI
On ovariectomized rat, substantially according to Gunness-Hey and Hock, the method for Metab.Bone Dis.5:177 181 (1984) is assessed the effect of compound of the present invention to sclerotin.
The Sprague-Dawley female rats of growing up is conformed, and both sides oophorectomize (OVX) or sham operated are carried out in grouping (n=9,10 or 12) then by weight.In operation administration in back 17 days, continue 20 days.Every day is with 2% mouse serum/brine media subcutaneous administration test compounds.
After 20 days, kill mouse, take out right femur.Femur is cut in half, and half femur (DHF) of far-end further is divided into trabecular bone (TB) and osteoderm (CB) by getting out girder.Extract calcium, measure by Calcette calcium analyser, represent with average bone calcium, unit is the mg/DHF/100g body weight.
Use two sample t-to check comparison OVX and simulation group.Compare the OVX group with unidirectional ANOVA, the LSD multiple comparisons method with Fisher compares each group with medium subsequently.
The oophorectomize meeting causes serious total deossification, mainly is the deossification of trabecular bone.Compare total calcareous low 47-54% of bone with the control group of sham operated.
Show that by statistics 80 micrograms/kg/ days bPTH (1-34) and hPTHrp (1-34) can make the calcareous obvious increase of total bone of the OVX mouse of handling, are respectively 53-95% and 18-40%; Obviously do not increase but osteoderm is calcareous.
Compound of the present invention during by administration in 80 micrograms/kg/ days, can increase the calcareous about 66-138% of total bone, increases the calcareous 87-128% of trabecular bone.For untreated OVX control group, calcareous, little cantilever thickness of osteoderm and bone volume also obviously increase.
In this is analyzed, tested following compounds: (% increases the calcareous numbering of the calcareous total bone of compound n trabecular bone (test number #), OVX) (% increases, OVX) compound 16 101-128% 88-138% compounds 23 87-102% 66-114% compounds 4 3-88-114%
In similarly studying, press and gave ovariectomized rat administration 5 in 40 micrograms/kg/ days, 10 and 20 days, obtain following result: (d) (% increases the calcareous numbering of the total bone of compound n administration fate (test number #), OVX) compound 13 20d 73-109% compounds 45 20d 79-105% compounds 41 10d 79% compound 49 1 10d 93% compound 41 5d 55% compound 42 1 5d 60%
The embodiment XII
Toxicity
In the superincumbent embodiment XI, do not observe toxic action for compound of the present invention.
Claims (12)
1. a Rat parathyroid hormone 1-34 PTH, parathyroid hormone-related peptide PTHrp and the short homologue of PTH and PTHrp and the synthetic polypeptide analog of analogue, or its salt, it is characterized in that, the amino acid of PTH and PTHrp (22-31) forms amphipathic alpha-helix, and the sequence of this residue (22-31) is selected from:
A) Xaa
1Xaa
2Leu Xaa
4Xaa
5Leu Xaa
7Xaa
8Xaa
9Xaa
10Wherein
1 5 10
Xaa
1And Xaa
4Be Glu independently of one another, Glu (OCH
3), His, or Phe; Xaa
2Be Leu or Phe; Xaa
5Be Lys or His; Xaa
7And Xaa
10Be Leu or Ile independently of one another; Xaa
8Be Ala, Arg, or Glu; And Xaa
9Be Lys or Glu (SEQ IDNO:26); Condition is that following situation can not occur simultaneously:
Xaa
1And Xaa
4All be Glu;
Xaa
2Be Leu;
Xaa
5Be Lys;
Xaa
7And Xaa
10All be Leu;
Xaa
8Be Arg or Glu; With
Xaa
9Be Lys, perhaps
B) Xaa
1Xaa
2Leu Xaa
4Arg Leu Leu Xaa
8Arg Leu wherein
1 5 10
Xaa
1And Xaa
4Be Glu independently of one another, Glu (OCH3), His, or Phe; Xaa
2Be Leu or Phe; Xaa
8Be Glu, Lys, or Lys (COCH
2PEGX) and PEGX be that molecular weight is 100-10, poly-(Ethylene Glycol Methyl ether) residue (SEQ ID NO:27) of 000; Condition is that following situation can not occur simultaneously:
Xaa
1And Xaa
4All be Glu;
Xaa
2Be Leu.
2. polypeptide as claimed in claim 1 and pharmacy acceptable salt thereof is characterized in that it has following formula:
Xaa
1?Xaa
2?Xaa
3?Xaa
4?Xaa
5?Xaa
6?Xaa
7?Leu?His?Xaa
10?Xaa
11?GlyXaa
13?Ser?Ile?Gln?Xaa
17?Leu?Xaa
19?Xaa
20?Xaa
21?Xaa
22-31?Xaa
32?Xaa
33Xaa
34?Xaa
35?Xaa
36?Xaa
37?Xaa
38?Term,
Wherein:
Xaa
1Disappearance or Ala;
Xaa
2Disappearance or Val;
Xaa
3Disappearance or Ser;
Xaa
4Disappearance or Glu or Glu (OCH
3);
Xaa
5Disappearance or His or Ala;
Xaa
6Disappearance or Gln;
Xaa
7Disappearance or Leu;
Xaa
10And Xaa
17Be Asp or Asp (OCH independently of one another
3);
Xaa
11Be Lys, Arg, or Leu;
Xaa
13Be Lys, Arg, Tyr, Cys, Leu, Cys (CH
2CONH (CH
2)
2NH (biotinyl)), Lys (7-dimethylamino-2-oxygen-2H-1-chromene-4-ethanoyl), or Lys (dihydro cinnamon acyl group);
Xaa
20Be Arg or Leu;
Xaa
19And Xaa
21Be Lys independently of one another, Ala, or Arg;
Xaa
22-31As defined in claim 1;
Xaa
32Be His, Pro, or Lys;
Xaa
33Disappearance, or Pro, Thr, Glu, or Ala;
Xaa
34Disappearance, or Pro, Arg, Met, Ala, hSer, the hSer lactone, Tyr, Leu, or 1,4-diamino butyryl lactan;
Xaa
35Disappearance or Pro, Glu, Ser, Ala, or Gly;
Xaa
36Disappearance or Ala, Arg, or Ile;
Xaa
37Disappearance or Arg, Trp, or 3-(2-naphthyl)-L-Ala;
Xaa
38Disappearance or Ala or hSer or Xaa
38-42Be Thr Arg Ser Ala Trp;
With Term be OR or NR
2, wherein each R is H independently of one another, (C
1-C
4) alkyl or phenyl (C
1-C
4) alkyl.
3. polypeptide as claimed in claim 2 is characterized in that Xaa
22-31Be sequence Xaa a) and wherein in the claim 1
11And Xaa
13All be Lys; Xaa
19And Xaa
21All be Arg.
4. polypeptide as claimed in claim 3, it is characterized in that it is Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile GlnAsp Leu Arg Arg Arg Phe Phe Leu Glu Lys Leu Leu Glu Lys Leu HisThr Ala NH
2(compound 50).
5. polypeptide as claimed in claim 3, it is characterized in that it is Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile GlnAsp Leu Arg Arg Arg Glu Leu Leu His Lys Leu Leu Glu Lys Leu HisThr Ala NH
2(compound 51).
6. polypeptide as claimed in claim 3, it is characterized in that it is Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile GlnAsp Leu Arg Arg Arg Glu Leu Leu Glu His Leu Leu Glu Lys Leu HisThr Ala NH
2(compound 52).
7. polypeptide as claimed in claim 3, it is characterized in that it is Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile GlnAsp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Ile Ala Lys Leu HisThr Ala NH
2(compound 53).
8. polypeptide as claimed in claim 3, it is characterized in that it is Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile GlnAsp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Glu Ile HisThr Ala NH
2(compound 54).
9. a pharmaceutical composition is characterized in that, it contains polypeptide as claimed in claim 1 or its salt and the pharmaceutically acceptable carrier that hyperostosis adds significant quantity.
10. a PTH, PTHrp or the short homologue of PTH and PTHrp and the polypeptide analog of analogue, or the solid phase synthesis process of its salt, wherein the amino-acid residue of PTH or PTHrp (22-31) is modified and is formed amphipathic alpha-helix, and this residue (22-31) is selected from:
A) Xaa
1Xaa
2Leu Xaa
4Xaa
5Leu Xaa
7Xaa
8Xaa
9Xaa
10Wherein
1 5 10
Xaa
1And Xaa
4Be Glu independently of one another, Glu (OCH
3), His, or Phe; Xaa
2Be Leu or Phe; Xaa
5Be Lys or His; Xaa
7And Xaa
10Be Leu or Ile independently of one another; Xaa
8Be Ala, Arg, or Glu; And Xaa
9Be Lys or Glu (SEQ IDNO:26); Condition is that following situation can not occur simultaneously:
Xaa
1And Xaa
4All be Glu;
Xaa
2Be Leu;
Xaa
5Be Lys;
Xaa
7And Xaa
10All be Leu;
Xaa
8Be Arg or Glu; With
Xaa
9Be Lys, perhaps
B) Xaa
1Xaa
2Leu Xaa
4Arg Leu Leu Xaa
8Arg Leu wherein
1 5 10
Xaa
1And Xaa
4Be Glu independently of one another, Glu (OCH
3), His, or Phe; Xaa
2Be Leu or Phe; Xaa
8Be Glu, Lys, or Lys (COCH
2PEGX) and PEGX be that molecular weight is 100-10, poly-(Ethylene Glycol Methyl ether) residue (SEQ ID NO:27) of 000; Condition is that following situation can not occur simultaneously:
Xaa
1And Xaa
4All be Glu;
Xaa
2Be Leu,
This method comprises in order that protected amino acid is coupled in the appropriate resin carrier, removes side chain and N
α-blocking group, and with polypeptide cracking from the resin carrier.
11. a PTH, PTHrp or the short homologue of PTH and PTHrp and the polypeptide analog of analogue, or the preparation method of its salt, wherein the amino-acid residue of PTH or PTHrp (22-31) is modified the amphipathic alpha-helix of formation, and this residue (22-31) is selected from:
A) Xaa
1Xaa
2Leu Xaa
4Xaa
5Leu Xaa
7Xaa
8Xaa
9Xaa
10Wherein
1 5 10
Xaa
1And Xaa
4Be Glu independently of one another, Glu (OCH
3), His, or Phe; Xaa
2Be Leu or Phe; Xaa
5Be Lys or His; Xaa
7And Xaa
10Be Leu or Ile independently of one another; Xaa
8Be Ala, Arg, or Glu; And Xaa
9Be Lys or Glu (SEQ IDNO:26); Condition is that following situation can not occur simultaneously:
Xaa
1And Xaa
4All be Glu;
Xaa
2Be Leu;
Xaa
5Be Lys;
Xaa
7And Xaa
10All be Leu;
Xaa
8Be Arg or Glu; With
Xaa
9Be Lys, perhaps
B) Xaa
1Xaa
2Leu Xaa
4Arg Leu Leu Xaa
8Arg Leu wherein
1 5 10
Xaa
1And Xaa
4Be Glu independently of one another, Glu (OCH
3), His, or Phe; Xaa
2Be Leu or Phe; Xaa
8Be Glu, Lys, or Lys (COCH
2PEGX) and PEGX be that molecular weight is 100-10, poly-(Ethylene Glycol Methyl ether) residue (SEQ ID NO:27) of 000; Condition is that following situation can not occur simultaneously:
Xaa
1And Xaa
4All be Glu;
Xaa
2Be Leu,
This method comprises: the gene of expressing this polypeptide of coding.
12. the purposes of a compound as claimed in claim 1 or its pharmacy acceptable salt is characterized in that, it is used to prepare treatment Mammals sclerotin and reduces situation, especially treats the medicament of osteoporosis.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1993/006465 WO1994001460A1 (en) | 1992-07-14 | 1993-07-13 | Analogs of pth and pthrp, their synthesis and use for the treatment of osteoporosis |
WO93/06465 | 1993-07-13 | ||
WOPCT/US93/06465 | 1993-07-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1127000A CN1127000A (en) | 1996-07-17 |
CN1070500C true CN1070500C (en) | 2001-09-05 |
Family
ID=22236755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN94192745A Expired - Lifetime CN1070500C (en) | 1993-07-13 | 1994-01-21 | Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN1070500C (en) |
WO (1) | WO1995002610A1 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5977070A (en) * | 1992-07-14 | 1999-11-02 | Piazza; Christin Teresa | Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis |
US5821225A (en) * | 1992-07-14 | 1998-10-13 | Syntex (U.S.A.) Inc. | Method for the treatment of corticosteroid induced osteopenia comprising administration of modified PTH or PTHrp |
US7410948B2 (en) | 1995-07-13 | 2008-08-12 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Analogs of parathyroid hormone |
US6544949B1 (en) | 1995-07-13 | 2003-04-08 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Analogs of parathyroid hormone |
US5723577A (en) * | 1995-07-13 | 1998-03-03 | Biomeasure Inc. | Analogs of parathyroid hormone |
US5955574A (en) * | 1995-07-13 | 1999-09-21 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. | Analogs of parathyroid hormone |
US5969095A (en) * | 1995-07-13 | 1999-10-19 | Biomeasure, Inc. | Analogs of parathyroid hormone |
TW505654B (en) | 1996-07-30 | 2002-10-11 | Hoffmann La Roche | Synthesis of analogs of PTH and PTHrP |
JP4142743B2 (en) * | 1996-07-31 | 2008-09-03 | ザ・ジェネラル・ホスピタル・コーポレイション | Novel peptide analogues related to parathyroid hormone |
PL195703B1 (en) * | 1997-09-09 | 2007-10-31 | Hoffmann La Roche | Treatment of bone fractures involving the use of pthrp analogues |
AU2003207512B2 (en) | 2002-01-10 | 2008-06-12 | Osteotrophin Llc | Treatment of bone disorders with skeletal anabolic drugs |
CN1950103B (en) * | 2004-05-04 | 2011-04-13 | 新陈代谢制药有限公司 | Application of growth hormone C-end fragment in pharmacy |
EP1945245A2 (en) | 2005-11-10 | 2008-07-23 | The Board of Control of Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
USRE49444E1 (en) | 2006-10-03 | 2023-03-07 | Radius Health, Inc. | Method of treating osteoporosis comprising administration of PTHrP analog |
SG175580A1 (en) | 2006-10-03 | 2011-11-28 | Radius Health Inc | Method of drug delivery for bone anabolic protein |
US8568737B2 (en) | 2007-08-01 | 2013-10-29 | The General Hospital Corporation | Screening methods using G-protein coupled receptors and related compositions |
US8987201B2 (en) | 2009-12-07 | 2015-03-24 | Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
WO2011143406A2 (en) | 2010-05-13 | 2011-11-17 | The General Hospital Corporation | Parathyroid hormone analogs and uses thereof |
CN106146648B (en) * | 2015-03-26 | 2020-06-12 | 深圳翰宇药业股份有限公司 | Synthetic method of parathyroid hormone analogue |
CA3045458A1 (en) * | 2016-11-30 | 2018-06-07 | Purdue Research Foundation | Fracture targeted bone regeneration through parathyroid hormone receptor stimulation |
US10996208B2 (en) | 2017-04-28 | 2021-05-04 | Radius Health, Inc. | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
CN107375910B (en) * | 2017-07-12 | 2020-03-24 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | Application of PTHrP in preparation of medicine for treating male hypogonadism syndrome |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0477885A2 (en) * | 1990-09-28 | 1992-04-01 | Takeda Chemical Industries, Ltd. | Parathyroid hormone derivatives |
WO1993006845A1 (en) * | 1991-10-10 | 1993-04-15 | Pang Peter K T | PARATHYROID HORMONE ANALOGUES SUBSTITUTED AT aa?25,26,27¿ AND USE IN OSTEOPOROSIS TREATMENT |
WO1994001460A1 (en) * | 1992-07-14 | 1994-01-20 | Syntex (U.S.A.) Inc. | Analogs of pth and pthrp, their synthesis and use for the treatment of osteoporosis |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2040264A1 (en) * | 1990-04-12 | 1991-10-13 | Tatsuhiko Kanmera | Parathyroid hormone antagonists |
-
1994
- 1994-01-21 CN CN94192745A patent/CN1070500C/en not_active Expired - Lifetime
- 1994-01-21 WO PCT/US1994/000589 patent/WO1995002610A1/en active Search and Examination
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0477885A2 (en) * | 1990-09-28 | 1992-04-01 | Takeda Chemical Industries, Ltd. | Parathyroid hormone derivatives |
WO1993006845A1 (en) * | 1991-10-10 | 1993-04-15 | Pang Peter K T | PARATHYROID HORMONE ANALOGUES SUBSTITUTED AT aa?25,26,27¿ AND USE IN OSTEOPOROSIS TREATMENT |
WO1994001460A1 (en) * | 1992-07-14 | 1994-01-20 | Syntex (U.S.A.) Inc. | Analogs of pth and pthrp, their synthesis and use for the treatment of osteoporosis |
Also Published As
Publication number | Publication date |
---|---|
WO1995002610A1 (en) | 1995-01-26 |
CN1127000A (en) | 1996-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1070500C (en) | Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis | |
CN1159341C (en) | Method for treatment of corticosteroid induced osteopenia | |
CN1051769C (en) | Peptides | |
CN1193915A (en) | Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis | |
CN1191273C (en) | Long lasting insulinotropic peptides | |
CN1305897C (en) | New peptide compounds, process for their preparation and pharmaceutical compositions containing them | |
CN1439021A (en) | Parathyroid hormone and parathyroid hormone-related protein receptor modulators | |
CN1283659C (en) | Truncated glial cell line-derived neurotrophic factor | |
CN1893980A (en) | Novel GLP-1 analogues linked to albumin-like agents | |
CN1225473C (en) | Method of preparing cyclic vasoactive peptides | |
CN1261281A (en) | Peptide parathyroid hormone analogs | |
CN1227567A (en) | Exendin analogues, processes for their preparation and medicaments containing them | |
CN1176947C (en) | Parathyroid hormone analogues for the treatment of osteoporosis | |
CN1902311A (en) | Novel recombinant proteins with n-terminal free thiol | |
CN1703424A (en) | GLP-1 derivatives and transmicosal absorption preparations thereof | |
CN1329620A (en) | Analogues of GLP-1 | |
CN1922313A (en) | Acid alpha-glucosidase and fragments thereof | |
CN1293096C (en) | Method for synthesis of analogs of parathyroid hormone and parathyroid hormone related peptide | |
CN1262688A (en) | Integrin binding peptide and use thereof | |
CN101056647A (en) | Vasoactive intestinal polypeptide pharmaceuticals | |
CN1500095A (en) | Polymer conjugates of neublastin and methods of using ssame | |
CN1328568A (en) | Peptide derivative | |
CN1212017A (en) | Hybrid proteins which form heterodimers | |
CN1871020A (en) | Antagonistic analogs of GH-RH (2003) | |
CN1170933C (en) | Motilin homologs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Expiration termination date: 20140121 Granted publication date: 20010905 |